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Chapter 1: Introduction To Prion Diseases And The Prion 
Protein  
 
Historical overview  
In 1982, the term "prion" was introduced by Stanley B.Prusiner, to christen a particle 
that, on the basis of clinical and biochemical observations, appeared to be a totally new 
infectious agent, consisting only of an endogenous cell surface protein [1-3]. This term 
is a combination of the two adjectives proteinaceous and infectious. The cellular form of 
the prion protein (PrPC) is hypothesised to be able to induce transmissible spongiform 
encephalopathies (TSE) in mammals by changing its conformation through, an as yet, ill 
understood pathway, that results in the formation of a "disease-associated" isoform, 
called the "scrapie form" of the protein (PrPSc) [1], [4], [5]. In contrast, to the soluble, 
monomeric PrPC, PrPSc has been shown to have a high tendency to associate into 
insoluble aggregates, such as oligomers or amyloid fibrils, and induce a fatal 
degeneration of the central nervous system (CNS) in the regions where the aggregates 
accumulate [6], [7], [8], [9], [10]. 
TSE or prion diseases are a group of fatal neurodegenerative diseases, which affect the 
CNS of both humans and animals [3]. Although the pathology of TSE varies from case 
to case, in general it results in similar neuropathological features, e.g. vacuolation, 
astrocytosis, and neuronal loss [11] showing a “spongy” appearance in the brain. 
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The first recorded case of a TSE disorder, which was caused by the ‘scrapie’ prion 
protein, and affected British sheep, was identified and documented more than two 
hundred and fifty years ago [12] . Since then, scrapie disease of sheep and goats has 
been known under a multitude of names ("rubbers", "rickets", "goggles", "shakings" 
"shrewcroft" in England, "scratchie", "cuddie trot" in Scotland, "der Trab", "der 
Traberkrankheit" lub "die Zitterkrankheit" in Germany, "la maladie convulsive", "la 
maladie follie", "le tremblante" "la prurigo lombaire" in France and "trzêsawka" in 
Poland). One of the earliest scientific reports on scrapie was published in the 
"Agricultural Improvement Society at Bath, as a paragraph in the "General View of the 
Agriculture of Wiltshire" published by Thomas Davies in 1811 [13]. Interestingly, in 
1848, Roche-Lubin claimed that scrapie was caused by the sexual overactivity of rams 
or, alternatively, by the thunderstorms [13]. 
 The first author who believed that scrapie ("tremblante") was a viral disease, was 
Besnoit in 1899 whilst the transmissible nature of TSE was proven in the late 1930’s by 
the seminal experiments of Cuile and Chelle [14]. The contention that scrapie was an 
infectious disease caused by a filterable agent was accepted with a long-lasting 
scepticism. In 1938, W.S. Gordon, a deputy director of the famous Moredun Institute in 
Edinburgh, Scotland, repeated experiments of Cuille and Chelle using 697 animals of 
which ~200 developed scrapie [15, 16], [17]. The infectious nature of the scrapie agent 
was confirmed in 1935, when ~ 7% of 18,000 sheep vaccinated against Louping, 
developed scrapie [15, 16]. 
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This vaccine was produced from formalin-fixed sheep brains and where the scrapie 
infectivity could survive 0.35% on formalin for more than 3 months. World War II 
interrupted research, on scrapie, which had been continued by the research of D.R. 
Wilson [18]. Wilson’s research remained largely unpublished due to his reluctance to 
present data on such an unorthodox pathogen. However, the ‘scrapie’ community 
became well aware of the unusual properties of the scrapie agent, in particular, its high 
resistance to formalin and high temperature[19].  
In the next era of the history of prion discoveries, scrapie was transmitted from sheep to 
mice by Morris and Gajdusek [20] and from goats to Chandler mice [21]. This led to 
wide-scale laboratory research and the production of many whimsical hypotheses, with 
an average frequency approaching one every year or two. The infectious agent has 
been claimed to be a self-replicating membrane [22-24] a subvirus (not well envisaged) 
linked to a membrane with a "linkage substance" [25], a viroid [26], a spiroplasma [27] 
or a retrovirus-like element [28, 29]. 
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Fig. 1. A typical image of a sheep with a disease caused by scrapie. In this figure, wool loss through 
rubbing and gnawing can be seen at the head, basis of the tail, and the sides of both fore and hind limbs. 
If scratched on the back (along the spine) affected animals start nibbling ("Gnubbern") and licking their 
nose. Other typical symptoms of scrapie disease are often a change in behavior such as separation from 
the herd, hypersensibility to touch, nervousness and fear of sudden noises (such as clapping of hands). 
Changes in sensitivity such as pruritus (itching) and related loss of wool complete the clinical picture. 
Additional symptoms such as apathy, loss of reflexes, salivation etc. can occur but are less frequent. The 
disease duration can be from weeks to months, resulting ultimately in the death of the animal from the 
disease. (source http://www.thedoctorweighsin.com/journal/2007/11/3/prions-can-kill-you.html) 
 
Another animal TSE is transmissible mink encephalopathy (TME), which was 
recognized in ranch-raised mink by Gaylord Hartsough [30]. 
Another member of the family of TSE, is the chronic wasting disease (CWD). CWD is a 
transmissible neurological disease of deer and elk that produces small lesions in brains 
of infected animals. It is characterized by loss of body condition, behavioral 
abnormalities and death. CWD is classified as TSE due to clinical symptoms similar to 
scrapie in sheep. Since the 1960s CWD has affected captive mule deer, white-tailed 
deer, and Rocky Mountain elk in North America; in the 1990s, CWD has also been 
found in free-ranging deer and elk [31].  
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Human TSE can be classified into three different forms: sporadic, inherited, or acquired 
by infection. Approximately 85% of TSE cases occur sporadically, in the absence of any 
obvious trigger [32]. The inherited forms include Gerstmann–Sträussler–Scheinker 
syndrome (GSS) fatal familial insomnia (FFI) and ~15% of the cases of Creutzfeldt–
Jakob disease (CJD) [33-35]. 
The first recorded event of a TSE disorder in humans was kuru (Fig. 2), which was 
discovered by Zigas and Gajdusek (1957) [36, 37]. The elucidation of kuru opened a 
new field in human medicine and initiated 40 years of research, which has contributed 
enormously to our understanding of neurodegenerative disorders of the central nervous 
system, which includes Alzheimer’s disease [38, 39]. The name kuru came from the 
Fore language, which means to shiver or to shake from fever and cold. The Fore used 
the noun of the kuru-verb to describe the always-fatal disease, which principally affected 
their children (Fig. 2) and adult women. It has been and still is restricted to natives of the 
Fore linguistic group at Papua New Guinea’s Eastern Highlands and those neighboring 
linguistic groups, which intermarry with the Fore tribe. Ritualistic endocannibalism (i.e 
eating of the relatives as a part of a mourning ritual but not as an alimentary habit) was 
a practice not only in the kuru area, but in many surrounding Eastern Highland groups 
which never developed kuru. In the late 1930’s and 1940’s, many gold miners, 
protestant missionaries, and government officials made contacts with the northern 
periphery of the kuru region, and they and later anthropologists, became thoroughly 
familiar with the ritual endocannibalism of Eastern Highland peoples. When the fatal 
epidemic in the kuru region was announced, most of the local Caucasians made the 
obvious assumption that it must have been spread by the cannibalistic practices. 
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It was the publication of this disease by Gajdusek, which led to the first possible 
suggestions that scrapie in animals and kuru in humans could be linked to the same 
family of disorders and caused by the same protein [40]. In 1959, Gajdusek, received a 
letter from the veterinarian William Hadlow [41], which highlighted analogies between 
kuru and scrapie, and had been successfully transmitted experimentally by the French 
group in 1936 (for review [42]). 
 
Fig. 2. Example of people affected by kuru disease. A preadolescent child totally incapacitated by kuru 
in 1957. The child had such severe dysarthria that he could no longer communicated by word, but he was 
still intelligent and alert. He had spastic strabismus. He could not stand, sit without support, or even roll 
over; and had been ill for less than six months, and died within a few months of the time of photography 
[42].  
Gajdusek’s reply to Hadlow, resulted in him reconsidering the infectious aetiology of 
kuru. In view of the chronic cerebral infections, such as Iin syphilis, toxoplasmosis, and 
trypanosomiasis, inoculated laboratory rodents and monkeys were held for longer 
observation periods than had been carried out previously in 1957, therefore he was 
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attempting to obtain a better inoculum in the form of autopsied brain tissue (for review 
[40]). 
In light of these discussions, Gajdusek, successfully transmitted kuru to chimpanzees in 
1965 [36], followed later, by transmission of Creutzfeldt-Jakob disease [43] and GSS 
[44]. Fatal familial insomnia was finally transmitted in the late 1990s [45] [46]. 
A further animal TSE disorder was described in 1987, when Gerald A. H. Wells and his 
colleagues from the Central Veterinary Laboratory, described a case of a single cow, in 
the UK, with a novel form of a TSE disorder. This eventually was called bovine 
spongiform encephalophy (BSE). Incidentally, although the paper came out one year 
later, the first case of what turned out to be BSE was reported in a nyala (Tragelaphus 
angasii) by Jeffrey et al. [47].  
An epidemic of this disorder broke out in the UK, which reached a climax in 1992, where 
more than 35,000 cases were diagnosed. However, due to the implementation of strict 
farming measures and bans on the sales of gelatin since the peak of the epidemic, the 
number of BSE cases diagnosed in the UK, has seen a steady decline since; 1,443 
cows in 2000, 1,137 in 2001 and 438 in 2002. In relation to this TSE disorder, in1996, 
Will et al. reported a finding of a new variant of CJD (nvCJD or vCJD), which they 
suggested most probably resulted from transmission of BSE to humans [48]. This 
epidemiological conjecture was subsequently substantiated by laboratory studies [49, 
50], [51], [52, 53], [54]. The number of vCJD cases is still increasing albeit it more slowly 
since their discovery although discussions about the extent of the outbreak is become 
disturbing. On the other hand, the BSE epidemic and appearance of vCJD in humans, 
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has accelerated TSE research and changed it from a rather small obscure field into a 
major scientific endeavour.  
Human-to-human transmission of TSEs was confirmed by iatrogenic CJD cases caused 
by direct contact of the CNS with contaminated material during the course of medical 
treatment [55]. 
In reality, prion diseases are still rare in humans [55], and up until the 1980s, knowledge 
of these diseases was limited to a small community of neuroscientists. However, since 
1986, from the recognition of BSE, (or ‘mad cow disease’) in combination with its spread 
in the UK, where more than 180,000 cattle were affected[56]. Attention to prion 
diseases has increased substantially from both the scientific and public communities 
[57]. BSE is believed to have been transmitted to humans by consumption of 
contaminated beef products, and it is believed to have resulted in the outbreak of the 
novel form of vCJD in England [51]. As a result of this, TSE continue to draw enormous 
attention from the scientific and public communities, and has even resulted in the 
awarding of 2 Nobel Prizes, (Gadjusek 1976 and Prusiner 1997) for research in this 
field, a rarity for most scientific fields.[57]. 
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Fig. 3. The number of deaths from TSE in humans since 1990 in the UK. TSE in human have been 
analyzed from 1990. Case of TSE in human start decrease. (http://www.cjd.ed.ac.uk) 
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The prion concept – infectious proteins 
The protein-only hypothesis was first outlined in general terms by Griffith [4], and 
formulated in more detail by Stanley B. Prusiner, [2]. It states that the partially protease-
resistant and detergent-insoluble PrPSc is identical with the infectious agent and that the 
infectious agent is devoid of nucleic acid. Additionally, the propagation of the agent is 
mediated by PrPSc and requires a conformational change from PrPC to PrPSc. Prions are 
formed by a post-translational conformational remodeling event in which a cellular 
protein, PrPC, is converted into the disease-associated infectious form, PrPSc and can 
be differentiated from PrPC by an increased resistance to digestion with proteases such 
as proteinase K (PK), poor solubility in non-ionic detergents, an increased β-sheet 
content, and its propensity for forming higher order structures such as oligomers 
amyloid fibrils [2]. The protein-only hypothesis is unique in offering explanations for all 
three etiologies of prion diseases (Fig. 4). In infectious disease, exogenous PrPSc enters 
the host, recruits copies of host-encoded PrPC and then templates their conversion, 
resulting in prion replication and disease pathogenesis. In the literature, protease 
resistant PrP (formed by the digestion of PrPSc with PK) is frequentally referred to as 
PrPres (or PrP27-30) in order to distinguish it from full-length PrPSc (Fig. 4 and Fig. 5). 
The use of the term PrPSc implies that the protein is infectious, whereas PrPres does not 
necessarily imply infectivity. 
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Fig. 4. Prion disease nomenclature and modes of acquisition. A: In prion disease, the host-encoded 
cellular prion protein (PrPC) undergoes a conformational transition to a disease-associated conformer 
termed PrPSc or PrPD. The approximate region of PrPC conformationally altered in PrPSc is shown in red, 
although the exact boundaries are unknown. Detection of prion disease is commonly achieved in vitro by 
treatment with PK, which cleaves PrPSc near residue 90, to generate the protease-resistant fragment 
termed PrPres or PrP27-30. B: Prion diseases are unique in the fact that they are infectious [58]. 
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Fig. 5. Differential susceptibility of PrPC and PrPSc to PK digestion. Demonstration of the different 
resistance of the protein with PK treatment. On the left the control sample (not abnormal PrP is present in 
the sample), on the right the abnormal PrPSc is resistent to PK treatment [58, 59]. 
 
Studies show that mammalian prions form fiber-like aggregates rich in β-sheet 
structures, which often have characteristics of a typical amyloid structure, being rod-like 
shape in electron micrographs and show apple-green birefringence under polarized light 
after staining with Congo red [2]. Amyloid fibers are also associated with other 
neurodegenerative diseases such as Alzheimer’s disease and Huntington’s disease. 
However, so far, it has been proven that only prion disorders can be transmitted. 
On the other hand, recent data has indicated that at least some amyloid-related 
disorders, once thought to be noninfectious, may also be transmissible under 
appropriate circumstances. For example, cerebral injection of brain homogenates from 
Alzheimer’s patients into transgenic mice expressing a mutant β-amyloid precursor 
protein has been shown to result in neuronal amyloid deposition and neurodegeneration 
within several months [60]. However, since control (untreated) animals used in these 
studies developed a similar disease pathology later in life, it was difficult to conclusively 
 17 
determine whether the diseased brain homogenate used in this study acts as a bona 
fide infectious agent or simply accelerates a predetermined clinical endpoint. Perhaps 
even more intriguing, are reports pointing to potential transmissibility of systemic 
amyloidoses in animals. In the case of mouse senile amyloidosis, marked 
apolipoprotein A-II amyloid deposition has been observed following either injection or 
oral ingestion of isolated apolipoprotein A-II fibrils [61]. Amyloid found in fecal matter 
and milk of these infected animals has also been demonstrated to induce amyloidosis, 
providing evidence for more natural routes of transmission [62]. For serum amyloid 
protein A, recent data suggests that amyloidosis may be transmitted from one species 
to another, where amyloid present in the feces of captive cheetahs was used to 
accelerate amyloidosis in mice treated with an inflammatory stimulus [63]. Whilst these 
studies have offered an intriguing glimpse into the relationship between amyloid and 
infection, it remains unclear whether prion-like transmission is a common property of all 
amyloid disorders under the appropriate experimental conditions. 
Most cases of TSE arise spontaneously, but the infectious nature and spread of the 
disease has attracted the greatest scientific and public interest. Whilst in the laboratory 
setting, the TSE agent is typically delivered by intracerebral inoculation into 
experimental animals, the most common mechanism for the natural spread of the 
disease is through ingestion. For example, strong evidence suggests that the feeding of 
BSE-contaminated meat and bone meal to livestock was responsible for the outbreak of 
BSE in the 1980s, in England, and subsequent consumption of diseased cattle by 
humans was believed to be responsible for the emergence of vCJD [64, 65]. 
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Neuroinvasion typically begins upon ingestion of the TSE agent. However, the process 
of infection remains unclear. One possible mechanism is depicted in Fig. 6. 
 
Fig. 6. Schematic representation of the potential mechanism of neuroinvasion in TSE. A: Inital 
uptake of the TSE agent from the intestinal lumen has been proposed to occur through a number of 
alternative mechanisms, including M cell transcytosis(i), ferritin-dependent trancytosis through intestinal 
epithelial cells (ii), or via direct capture by dendritic cells (iii). While phagocytic cells such as macrophages 
appear to degrade PrPSc (iv), dendritic cells may deliver the TSE agent to follicular dendritic cells (FDCs) 
where early accumulation of PrPSc occurs (v). B: After amplification of the TSE agent in lymphoid tissue 
such as the GALT and spleen, invasion of the nervous system is believed to proceed through peripheral 
nerves. Retrograde transport of the TSE agent is believed to occur along two distinct pathways, following 
efferent fibers of the sympathetic and parasympathetic nerves to the CNS. C: Retrograde transport and 
propagation of PrPSc along neuronal processes may occur by step-wise interactions along the cell surface 
(ia, ib), via extracellular deposits (ii), or by vesicle-mediated mechanisms (iiia, iiib) [65]. 
 
The mechanism seems possible due to the infective particle crossing the intestinal 
epithelium where probably microfold (M) cells play an important role [66]. Moreover, it is 
reasonable to postulate that the initial uptake of the TSE agent was made by migratory 
dendritic cells, which have the ability to capture antigens within the intestinal lumen. 
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Once past the epithelial wall, PrPSc is probably sphagocytosed by macrophages and or 
dendritic cells. Whilst macrophages appear to serve a more protective role [67], some 
experimental evidence suggests that dendritic cells can deliver the infective molecule to 
follicular dendritic cells located in the germinal centers of B cell-rich follicles present in 
Peyer’s patches and other gut-associated lymphoid tissue (GALT) underlying the 
intestinal epithelium (Fig. 6A). After incubation in lymphoid tissue, such as the GALT 
and spleen, PrPSc spreads to the CNS via the enteric nervous system. This invasion 
occurs in the retrograde direction along efferent fibers of both sympathetic (e.g., the 
splanchnic nerve) and parasympathetic (e.g., the vagus nerve) nerves [67] (Fig. 6B). It 
is unknown how the retrograde transport between synaptically linked peripheral nerve 
cells occurs: by step-wise interactions involving direct contact between PrPSc and 
surface PrPC along the axolemmal surface, through a vesicle mediated mechanism, or 
via free-floating extracellular aggregates (Fig. 6C). Once within the CNS proper, further 
retrograde transport of the TSE pathogen eventually results in infection of the brain, 
leading to characteristic spongiform degeneration and astroglial activation. 
Prion diseases are thus very important to study as they enlighten two important 
concepts in biology: (1) proteins can have different structures with the same primary 
structure but with different functions and (2) some structures can be infective because 
they are capable to self-replicate. 
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Prion diseases  
Mammalian prion diseases belong to a group of invariably fatal neurodegenerative 
disorders of both animals and humans, and are resultant of the self replication of the 
protein from its conversion of the host-encoded PrPC into a misfolded form (PrPSc) that 
tends to aggregate and may be neurotoxic [11]. There are four principle 
neuropathological observations for prion diseases (Fig. 7) spongiform change (vacuolar 
degeneration of brain parenchyma) death of neurons, astrocytic gliosis (in itself a non-
specific reactive response to CNS damage but of an unusual intensity in prion disease 
[68], and the presence of extracellular amyloid plaques in some, but not all, varieties of 
prion disease. The majority of prion diseases (including scrapie, mouse-adapted 
scrapie, BSE, and CJD) are characterized by large amounts of spongiform degeneration 
and the accumulation of PK-resistant PrP, but with little or no PrP amyloid plaque 
formation. 
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Fig. 7. The neuropathological hallmarks of prion disease. A: Spongiform (vacuolar) degeneration in 
the grey matter of the brain of a mouse infected with the RML strain of prions. Vacuolation of the brain 
(black arrows) is observed in most prion diseases and causes the degeneration of neuronal processes 
and eventually results in the death of neurons. B: Activation of astrocytes (reactive astrocytic gliosis: 
white arrows) in the brain of a patient with CJD as observed by immunostaining for glial fibrillary acidic 
protein (GFAP). (Image taken from [68]. C: Deposits of PrP amyloid as observed by 
immunohistochemistry in the brain of an elk infected with CWD (Image taken from [58] D: ‘Florid’ plaque 
(black arrow) consisting of a central PrP amyloid deposit surrounded by a halo of spongiform change in 
the brain of patient with vCJD. (Image taken from [48]) 
 
The mechanism(s) by which PrPSc causes disease are unclear. One study which used 
Prnp0/0 mice that had been grafted with Prnp+/+ tissue demonstrated that only the tissue 
which expressed PrPC was damaged, despite the large amounts of PrPSc in Prnp0/0 
tissue [69]. This suggests that the presence of PrPC is required for prion pathology and 
that PrPSc is not inherently neurotoxic. In contrast, in mice expressing PrPC exclusively 
in astrocytes, pathology in prion-inoculated mice has been observed in tissue 
surrounding astrocytes (i.e. in tissue lacking PrPC) whereas astrocytes remain 
undamaged [70]. Recent studies using transgenic mice expressing PrP lacking its GPI 
anchor (i.e. secreted PrP) have shown that these mice produce large amounts of PrPSc , 
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but fail to develop clinical prion disease following prion challenge [71]. This suggests 
that membrane anchorage of PrP is essential for prion pathology, perhaps implying the 
existence of a transmembrane protein which mediates PrPSc toxicity [72]. There is also 
considerable debate as to whether the accumulation of cytoplasmic PrP may play a role 
in prion toxicity. Transgenic mice expressing cytoplasmic PrP exhibit a 
neurodegenerative phenotype (albeit one that differs from classical prion disease) and 
accumulation of PrP in the cytoplasm results in the generation of a PrPSc-like molecule 
[73] [74]. However, other investigators have failed to find any toxic effect associated 
with cytoplasmic PrP [75]. 
The spectrum of prion diseases appears to be increasing and several new prion 
diseases of animals have recently been described [58]. Abnormal presentation of prion 
disease in two cattle in Italy was sufficiently distinct from BSE as to suggest a distinct 
neurological syndrome denoted bovine amyloidotic spongiform encephalopathy (BASE) 
[76] [77]} BASE is transmissible to mice confirming that it is a veritable TSE and 
strikingly, its properties in mice were indistinguishable from BSE suggesting that BASE 
may represent the original source of BSE [78]. Another disease, Nor98, sometimes 
referred to as atypical scrapie, was first detected in Norwegian sheep [79], [80]. There is 
no evidence of lateral or horizontal transmission, with cases (one per flock) observed in 
geographically dispersed locations. Furthermore, Nor98 possesses distinct genetic, 
biochemical, and histopathological signatures from scrapie. Nor98 is transmissible to 
mice, confirming its classification as a prion disease [81]. The origins of BASE and 
Nor98 are unclear, although it is conceivable that both represent distinct sporadic prion 
diseases of animals.  
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Prion strains are prion isolates, biologically cloned, which display unique biological 
properties and result in characteristic phenotypes when propagated in a given species. 
Strains can be identified and differentiated on the basis of clinical manifestation (such 
as the “scratching” and “drowsy” strains of scrapie when given to goats) [17], differential 
incubation times [82] pathological lesion profiles (i.e. different strains target different 
neuroanatomic areas of the brain) the ratio of glycoforms (unglycosylated, 
monoglycosylated and di-glycosylated) within protease-digested preparations of PrP 
[49], the size of the PK-resistant PrP fragment [83], [84] differential reactivity to 
luminescent conjugated polymers [85], [86], and other biochemical properties such as 
conformational stability [87]. The existence of prion strains comprises one of the main 
challenges to the protein-only hypothesis and opponents argue that such diversity 
cannot be encoded in the absence of a nucleic acid [88]. Indeed, multiple prion strains 
can exist for a given PrP amino acid sequence suggesting that strain variety is encoded 
by a different mechanism. Accumulating evidence suggests that strain-specific 
properties are encoded by the conformation of PrP. Subtle changes in conformation 
could lead to the phenotypic differences observed, such as differential sizes of PK-
resistant fragments and neuroanatomic target areas [84]. This hypothesis has not been 
definitively proven for mammalian prions to date, in large part due to the lack of high 
resolution structural data for PrPSc. Studies on various prion strains using the 
conformation-dependent immunoassay suggest that individual strains have differential 
availability of antibody epitopes implying that each strain has a different PrP 
conformation [9]. Also, small changes in amino acid sequence of a mutant PrP23-144 
molecule led to distinct ultrastructural properties of prion fibrils in vitro [89] [90]. 
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Furthermore, prion strains which are more susceptible to chemical denaturation have 
the shortest incubation times and vice versa suggesting that the conformational stability 
of a given strain governs it replication rate [91]. However, the strongest evidence for the 
conformational encoding of prion strains has come from studies on yeast prions. 
Amyloids of the Sup35 protein, prepared at different temperatures have led to unique 
conformations, which are stably propagated. When these variants are introduced into 
yeast, different strains of [PSI+] are obtained, suggesting that conformation of Sup35 
amyloid governs strain-specific [92]. Furthermore, the structural differences in Sup35 
strain variants have been probed by hydrogen/deuterium exchange revealing that 
differences in the length of the amyloid β-sheet core dictate strain structure and 
biological properties [93]. Nonetheless, the issue of prion strains will remain an open 
question in prion biology until parallel high-resolution structures exist for different strains 
of mammalian prions. 
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The cellular form of prion protein - PrPC 
The PrPC protein is a widespread cell surface tethered protein expressed mainly in the 
tissues of the CNS. Mature PrPC is a ~210 amino acid protein which largely localizes to 
detergent-resistant subdomains known as ‘lipid rafts’, located on the outer surface of the 
plasma membrane via a C-terminal glycophosphatidylinositol (GPI) anchor (Fig. 8) [3] 
[94]. 
 
Fig. 8. GPI-anchored plasma-membrane glycoprotein. Picture highlights the three-dimensional 
structure of PrPC. Here is depicted the glycosilation site and the putative copper binding site (from [95]). 
 
 
Moreover, mature PrPC undergoes endoproteolysis at the cell surface, being subjected 
to two posttranslational cleavages during the course of its metabolisms. The ‘normal' 
constitutive cleavage of PrPC, in the brain and in cultured cells, occurs inside this 
neurotoxic region of the protein (between residues 110 and 111), leading to the 
formation of a 9 kDa soluble N-terminal fragment (N1; residues 23–110) and a 17 kDa 
C-terminal fragment (C1 or PrP-II) that is still attached to the membrane through the 
GPI anchor [96], [97]. 
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Any modification can have an effect on the topology and the function of the PrP. In fact, 
the PrP protein has been observed in many topological forms and each could be 
expressed for different roles and interactions for the protein. Due to the fact that the 
majority of PrP is found outside of the membrane, it is possible that during its passage 
to the plasma membrane, the mature protein could take on different partial structures 
and features such as transmembrane variants or cytoplamatica variants. Many authors 
have speculated about this but as of yet, nothing is conclusive [98, 99]. 
High-resolution magnetic resonance nucleic (NMR) studies of bacterially expressed 
recombinant (rec) PrP, a model for PrPC lacking any post-translational modifications, 
have revealed a folded C-terminal domain and an N-terminal region which is largely 
unstructured [100]. Depending on the species, the flexible N-terminus contains at least 
four glycine-rich octapeptide repeats which display a particular affinity for Cu2+ [101], 
with reports of weaker binding to other divalent cations such as Zn2+, Fe2+, Ni2+, and 
Mn+2 [102] (Fig. 8-9). 
The PrP globular domain is highly conserved over many different species, consisting of 
two short β-strands and three α-helices, with a disulfide bond bridging helices 2 and 3. 
This domain also contains two potential sites for N-linked glycosylation (Fig. 9) [100]. 
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Fig. 9. Model of three-dimensional prion protein. PrP protein is made of a globular domain (amino acid 
121-231) which includes three α-helices and two small antiparallel β-sheet structures, and a long flexible 
tail whose conformation depend on the environment condition (from [59]) 
 
 
The physiological function(s) of PrPC 
The physiological function of PrPC remains elusive. Much hope was pinned on the use 
of PrPC knock-out mice to unveil the function of the protein, but no obvious phenotype 
was observed [103]. Even postnatally induced Prnp ablation does not elicit any 
phenotype [104]. Aging mice show demyelination in the peripheral nervous system, 
albeit without clinical symptoms [105]. A number of subtle abnormalities, e.g. 
abnormalities in synaptic physiology [106] and in circadian rhythms and sleep [107] 
have been described in PrP-deficient mice, but their molecular basis is undefined. The 
only definite phenotype of Prnp0/0 mice is their resistance to prion inoculation [103]. 
An astonishing number of independent lines of mice lacking PrPC have been generated 
by homologous recombination in embryonic stem cells in many laboratories. Mice with 
disruptive modifications restricted to the open reading frame are known as Prnp0/0 
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[Zurich I] [103] or Prnp−/− [Edinburgh] [108]. They developed normally, and no severe 
pathologies were observed later in life. As predicted by the protein-only hypothesis, 
these mice were entirely resistant to prion infections [103]. 
Several physiological roles for PrPC have been proposed; cell adhesion, signaling, 
neuroprotection and metabolic functions related to its copper-binding properties. Cell 
culture experiments reveal a constitutive internalization process of PrPC from the 
plasma membrane into endocytic organelles, yet most of the protein recycles back to 
the membrane without degradation [109]. The existence of a recycling pathway 
suggests that one physiological role of PrPC may be to serve as a receptor for uptake of 
an extracellular ligand. One attractive candidate for such a ligand is the copper ion. It 
has been shown that copper ions, at physiologically relevant concentrations, rapidly and 
reversibly stimulate endocytosis of PrPC from the cell surface [110]. 
Moreover, it has been reported that PrPC can bind copper ions and possesses 
superoxide dismutase activity [111]. Additionally, amino-proximal truncated PrPC 
appears to depress endogenous dismutase activity [112], suggesting a role for copper 
binding of the N-terminal octapeptide-repeat segment. However, PrPC does not make 
any measurable contribution to dismutase activity in vivo [113]. Given the localization of 
PrP as a GPI-anchored protein in rafts or caveolate, it has been proposed that PrP, as 
with other GPI-anchored proteins, could be involved in signal transduction [95]. 
Crosslinking of PrPC with F(ab)’2 antibody fragments has been reported to activate Fyn 
tyrosine kinase [114]. Since Fyn is associated with cellular proliferation and cellular 
survival, cell surface PrP might modulate neuronal survival. However, it has been 
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reported that PrP-mediated Fyn activation in cerebellar granule neurons might be 
responsible for neurite outgrowth rather than neuronal survival [96]. Other studies 
indicate that PrPC may interact with components of signal transduction pathways, such 
as Grb2 [115]. Grb2 is an adaptor protein that mediates growth factor receptor signals 
and also plays an important role in neuronal survival. Engagement of PrPC with certain 
antibodies, a PrPC binding peptide [116] or with a molecule called stress-inducible 
protein I (STI 1), leads to activation of both the cAMP/ protein kinase A and the Erk 
signaling pathways [117] [118]. PrPC-mediated activation of the cAMP/ protein kinase A 
(PKA) pathways has a cytoprotective effect in nervous tissue [118]. Taken together, 
these studies clearly support a neuroprotective role for PrP through signal transduction 
events. 
PrP has been shown to interact with the 37 kDa/67 kDa laminin receptor precursor 
[119], [120], and heparan sulfate [120], suggesting a possible role in cell adhesion 
and/or signaling. Perhaps PrPC does not possess any intrinsic biological activity, yet it 
modifies the function of other proteins. Multiple PrPC interacting partners have been 
identified in recent years: the antiapoptotic protein Bcl-2 [121], caveolin [122], N-CAM, 
[123] and neurotrophin p75 receptor [124]. None of these interactors, however, have yet 
revealed functional pathways in which PrPC could be involved in vivo. 
PrPC associations with raft membranes, adhesion molecules and signalling pathways 
are consistent with its involvement in the assembly of new cellular structures such as 
neurites and synapses in neurons, and projections in leukocytes (pseudopodia) and 
follicular dendritic cells (dendritic processes). At the same time, there is evidence that 
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PrPC negatively modulates the phagocytic activities of macrophages and other 
phagocytic cells in a manner that might control inflammatory responses to damaged or 
apoptotic cells [65]. Notably, PrPC is expressed at relatively high levels in the brain, 
where overly aggressive inflammatory responses might be particularly damaging and 
irreversible. One curious characteristic of PrPC that is not obviously connected to the 
assembly of cellular structures, but might be related to clearance or scavenging 
mechanisms, is its propensity to bind metals, nucleic acids, porphyrins and their 
analogues. The presence of free forms of these PrPC ligands in the extracellular spaces 
would ordinarily be unexpected, unless they were released from pathogens, dying or 
damaged cells, or perhaps debris from decommissioned cellular structures such as 
under-used axons, dendritic spines and synapses. The detection and control of 
potentially harmful factors is an important part of the responses of the innate immune 
system and glia to infections, tissue damage, stresses, developmental changes (such 
as apoptosis) and restructuring. It is tempting to speculate that PrPC might modulate 
such responses in various cell types by scavenging nucleic acids, metals, porphyrins 
and similar factors for delivery to appropriate receptors or subcellular sites for 
degradation and/or signalling. In this context, the binding of PrPC by cell-surface GAGs 
might keep PrPC molecules occupied until preferred ligands appear, because GAGs can 
compete for the same sites on PrPC [125]. Most of the known PrPC ligands - for 
example, NCAMs, laminins, laminin receptors and HSPGs - are involved in cellular 
adhesion, and these molecules, and their binding partners, are notorious for being 
polymorphic. Thus, one likely possibility is that PrPC functions as a part of complexes 
comprising multiple proteins and membrane subdomains that are modulated by cell 
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type, developmental stage, differentiation state, and both extracellular and intracellular 
cues (Fig. 10). 
 
Fig. 10. Model of potential PrPC interactions associated with axonal growth. PrPC seems to be 
important for neurite (nascent axon and dendrite) growth and synapse formation in neurons (from [95]).
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Chapter 2: Mechanism Of Prion Protein Conversion: Lessons 
From In Vitro Studies 
 
Protein aggregation: oligomers vs amyloid fibrils; their toxic role they 
play in neurodegenerative diseases 
Proteins are essential parts of living organisms and participate in virtually every process 
within living cells. In the last several decades, a great deal has been learned about the 
various structural forms that the protein molecules adopt in their native states and their 
functional roles in cellular systems. Moreover, we are also beginning to have a basic 
understanding of the complex protein folding mechanism at a molecular level and how 
biological systems have evolved to optimize the protein structure and to ensure the 
correct folding of proteins. In more recent years, this knowledge has led to the 
development of numerous computational methods that predict the structures and 
functions of proteins from their genomic information, which has become largely 
available from the various genome projects.  
Due to the importance of proteins and their roles in cellular systems, failure to 
synthesize, or misfolding of proteins, may cause the malfunctioning of cellular 
mechanisms and serious harm to the host organism. Thus, biological systems have 
evolved elaborate protection procedures to prevent this failure to synthesize or 
misfolding of proteins by detection and degradation of proteins when misfolding occurs.  
However, despite these inherent cellular level controls to prevent protein’s misfolding 
events, a number of human diseases are still associated with protein misfolding and the 
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subsequent aggregation of proteins [126, 127]. This includes a wide range of diseases 
from cystic fibrosis and familial emphysema to non-neuropathic systemic and localized 
diseases such as Type II diabetes, and neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and prion diseases 
[128], [129]. These diseases are often inherited and sporadic, but they can also be 
infectious like in the case of prion diseases. Each disease is associated with a particular 
protein or aggregates of these proteins, which are thought to be the direct or indirect 
cause of the pathological conditions associated with the disease [127]. 
Lately, most research has focused on a group of diseases that involve protein 
misfolding or the destabilization of the normal soluble structure of proteins followed by 
subsequent conversions to insoluble fibrillar aggregations, which accumulate in a 
variety of organs including the liver, spleen and brain [130]. These fibrillar forms of 
ordered aggregates are known as amyloid. Although proteins that are involved in these 
amyloid diseases are structurally and evolutionarily unrelated in their native states, the 
misfolded fibrillar form of proteins bear similar features. 
Abnormal protein aggregation is a key feature of a number of other neurodegenerative 
diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases and 
amyelotrophic lateral sclerosis [131] [132]. These protein aggregates share several 
physicochemical features: a fibrillar morphology, a predominantly β-sheet secondary 
structure, birefringence upon staining with the dye Congo red, insolubility in common 
solvents and detergents, and protease-resistance. None of the polypeptides implicated 
in these diseases exhibit any primary sequence homology, nor do they derive from 
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similar sources. However, non-conservative gene mutations have been identified for 
each of these disorders, contributing to protein misfolding, aggregation and eventual 
deposition in neuronal inclusions and plaques. These diseases lead to extensive 
degeneration of neurons. 
In Huntington’s disease, neuronal loss is believed to be directly mediated through the 
aggregated state of the huntingtin protein [133]. In other cases (for example the β-
amyloid and α-synuclein proteins in Alzheimer’s and Parkinson’s disease, respectively), 
presumptive neurotoxic oligomeric protein-intermediates, referred to as protofibrils, have 
been suggested to mediate cell death [134].  
In prion diseases, the precise role of misfolded, aggregated PrPSc in the 
neurodegenerative process remains controversial. The protein-only prion hypothesis of 
protein replication [4] [2], states that the prion (of which PrPSc constitutes the major, if 
not sole component) is the infectious and neurotoxic agent. However, work by Brandner 
et al. [69] and recently by Mallucci and coworkers [135] provide evidence in vivo that 
accumulation of PrPSc in the brain per se, may not cause neurodegeneration. Rather, 
this neurotoxicity may be mediated by the conversion of PrPC to disease-associated 
isoforms, PrPSc, specifically within or on neurons expressing PrP. Or, because PrPSc 
binds PrPC [136] it may cause a loss or alteration of the physiological function of PrPC. 
However, postnatally induced Prnp ablation does not elicit any phenotype [104] hence 
prion pathology is unlikely to come about by a loss of PrPC function. 
A general mechanism for neurotoxicity in all neurodegenerative diseases based on 
protein aggregation has recently been suggested [137] [138] [139]. Bucciantini and 
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colleagues demonstrated that the aggregation of non-disease associated proteins 
exhibit inherent cytotoxicity. Moreover, it has recently been demonstrated that different 
types of soluble amyloid oligomers potentially share a common structure that is 
recognized by a single antibody, irrespective of the primary amino acid sequence [138]. 
The binding of this antibody neutralizes the cytotoxic effects of these oligomers, again 
suggesting a common mechanism of toxicity for all these oligomers. However, despite 
this recent progress, understanding of the precise pathophysiological mechanisms that 
eventually lead to the death of neurons is currently lacking. 
For more than forty years amyloid deposits were believed to be the causative agents in 
the degenerative process [140]. Although many studies supported this notion, newer 
studies with improved techniques are challenging this view [141]. In fact, the current 
thinking is that it is a group of still poorly defined pre-amyloid species, rather than the 
amyloid deposits themselves, that are the true toxic conformations [138] [142]. 
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A structural view on amyloid fibrils  
The term amyloid was introduced in 1854 by the German physician scientist Rudolph 
Virchow [143]. Utilizing the best scientific methodology and medical knowledge 
available at the time, Virchow used iodine to stain cerebral corpora amylacea that had 
an abnormal macroscopic appearance. The macroscopic appearance of the brain tissue 
was similar to previous descriptions of other tissues, perhaps as early as 1639, as 
lardaceous liver, waxy liver, and spongy and “white stone” containing spleens. During 
the 19th and early 20th centuries, investigations on the nature of amyloid evolved from 
the macroscopic observations of Virchow and contemporaries to classifications of 
clinical symptoms. 
The term amyloid is often used in different ways. In the context of diseases it was 
defined by the Nomenclature Committee of the International Society of Amyloidosis as 
”extracellular depositions of protein fibrils with characteristic appearance in electron 
microscope, typical X-ray diffraction pattern, and affinity for Congo Red with 
concomitant green birefringence” [144]. 
Amyloid fibrils may form with distinct kinetics. Amyloid fibril formation typically shows a 
kinetic curve typical of a nucleation mechanism with a characteristic lag phase. Seeding 
of the amiloid formation solution with preformed fibrils can shorten this lag phase [128] 
(see Fig. 11, below for more details). Before formation of mature fibrils, prefibrillar 
aggregates, sometimes termed amorphous aggregates, occur which can have a 
spherical shape. Interestingly, specific antibodies can be designed which bind to the 
prefibrillar aggregates of different proteins but not to the mature fibril [138]. 
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 Furthermore, it has been demonstrated that the prefibrillar aggregates are generally 
more toxic to cells than the mature amyloid fibrils [145]. This led to the speculation that 
amyloid cytotoxicity is based on the structural properties of the prefibrillar aggregates 
[145]. However, little direct data exists on how the structure of the prefibrillar aggregates 
compares with the arrangement of the polypeptide chain in mature amyloid fibrils to truly 
validate this belief.  
Amyloid fibrils also exhibit certain distinctive features. They may be long fibril entities 
(µm range) with lateral dimensions in the range of 6–13 nm with a distinctive X-ray 
diffraction fingerprint that results from the cross-β structure (Fig. 11). 
They share a common molecular skeleton, the protofilament core structure, which is a 
continuous β-sheet assembly [146]. 
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Fig. 11. Amyloid structure. Hierarchy of structure from protein folded into a β-plated structure to amyloid 
fibril. The 4.7 Å correspond to the hydrogen bonding distance between two β-strand, the 11 Å correspond 
to the distance between β-sheet and the 60-80 Å distance corresponds to an average fibril diameter 
(adapted from [147]). 
 
The X-ray diffraction reflections at approximately 4.7 Å on the meridian and 10 Å on the 
equator are characteristics of fiber diffraction pattern for all amyloids. The structural 
repeat of 4.7 Å along the fibre axis corresponds to the spacing of β strands and the 10–
12 Å spacing corresponds to the face to face separation of the β sheets [148]. 
Whilst little structural data, exists on whether prefibrillar aggregates and mature fibrils 
are similar, one study on Aβ(1-40), has shown that the fold of the toxic prefibrillar 
aggregates and the mature amyloid fibrils are similar [149].  
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Mature fibrils are the end point of the aggregation process and thus are easily 
accessible for structural studies. Due to the non-crystalline insoluble nature of amyloid 
fibrils a variety of methods has been applied to elucidate their structure. The most 
widely applied technique is electron microscopy, which typically shows straight, 
unbranched amyloid fibrils, which are 0.1-1.6 µm in length and have a diameter of 60-
120 Å. They are built from protofibrils with a diameter of 25-35 Å [147]. Similar proteins 
may form amyloid fibrils with different morphologies exhibiting a twist of the fibril or 
lateral association forming an untwisted fibril. Oriented amyloid fibrils show a typical so-
called cross-β X-ray diffraction pattern with a meridional 4.6-4.8 Å spacing, which results 
from the main chain distance within β-sheets running parallel to the fibril axis [148]. The 
variable equatorial 8-12 Å spacing corresponds to the distance between two β-sheets 
[145]. Interestingly, amyloid fibrils show a different amide I’ band in FTIR spectra in 
comparison with native β-sheet-rich globular proteins [150]. However, it is the 
underlaying common structural properties of amyloid fibrils lead to specific reactions 
with staining dyes (Congo Red [151], Thioflavin T [152] and antibodies [153]). 
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In vitro conversion studies 
The available experimental evidence in vitro indicates that the kinetics of fibril formation 
are complex and can be often separated into a nucleation (or lag) phase and an 
elongation phase (Fig. 12), followed by the equilibrium between isolated polypeptides 
and the fibrils [154], [153]. Moreover, multistep kinetics, with the presence of 
intermediates have also been reported [155]. 
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Fig. 12. Mechanism of prion replication and the seeding–nucleation model of amyloid formation. 
Compelling evidence suggests that PrPC to PrPSc conversion as shown in (A) follow a crystallization-like 
process known as ‘seeding–nucleation’. In this model, formation of a stable oligomeric structure that is 
capable of further sustaining and catalyzing polymerization of the protein is the key and kinetically limiting 
step. A: The kinetics of amyloid formation usually exhibits an initial lag phase, in which no detectable 
amyloid is formed, whereas monomers nucleate to form fibers when mixed together with a fresh pool of 
soluble protein. Moreover, fragmented amyloid fibrils can shorten the lag phase and initiate rapid amyloid 
formation; a phenomenon known as seeding; B: Amyloid formation consists of two kinetic phases. In the 
‘lag phase’, oligomeric nuclei are formed in a slow process that involves misfolding of the protein and 
unfavorable intermolecular interactions. Once these ‘seeds’ are formed, a much more rapid ‘elongation 
phase’ results in fibril formation. The limiting step in the process is the formation of seeds to direct further 
aggregation [154]. Amyloid formation can be substantially accelerated by the addition of preformed seeds 
(circle line) representing the structure that is inherently infectious.  
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Pathways of fibril formation, fibril morphologies and stability of protofibrillar 
intermediates are influenced strongly by experimental conditions (e.g. protein 
concentration, pH and ionic strength [156]) and elongation rates can depend on the 
stability of aggregation of the protein and the folding intermediates [157]. In vitro 
generation of infectious prions from recombinant PrP is considered as the final proof of 
the “protein-only” hypothesis. In addition, compared to slow and costly conversion 
experiments in animals and cell culture [3], cell free conversion systems simplify the 
experimental environment, and opens an opportunity to understand the mechanism of 
the conversion. Many scientists endeavored to study in vitro PrP conversion (despite 
inherent caveats to the procedure) using short, synthetic PrP peptides [158-162]. 
Although these short peptides were found to form amyloid fibrils under certain 
conditions, their relevance has always been questioned since these fibrils have never 
been found to be infectious in vivo.  
Difficulties in purification of large quantities of PrPC from natural brain source and the 
insolubility of PrPSc are limiting factors in studying biophysical aspects of the PrPC → 
PrPSc conversion reaction. However, new opportunities for obtaining purer and larger 
volumes of protein are available from the development of expression systems for the 
production of recPrP [163]. The methods for production of PrP with either the presence 
or absence of tag are utilized for purification [164-166]. The use of a tag in the 
production of the protein gives the best possible results compared to systems without 
the use of the tag.  
 43 
Studies with human recPrP fragment corresponding to the Y145stop variant have 
demonstrated the possibility to transform the monomeric state in fibrillar state in vitro 
[167] and then use it for studies on the species barrier and strain diversity [89].  
Studies performed with other peptides such as PrP106–126, a region located near the 
N-terminal of the protease-resistant PrPSc has attracted interest, and has demonstrated 
toxicity in both in vitro and in vivo toxicity of aged 106–126 peptide in a rat retinal model 
[168]. Whilst these studies provide us some clues with regards to the enigmatic 
infectivity of prion diseases, they do not explain the process in its entirety. 
Moreover, it is known that a broad variety of proteins that rapidly fold into monomeric or 
oligomeric cellular forms under native-like conditions can also be refolded into β-rich, 
amyloid forms under conditions that destabilize the native state [126]. 
In recent years, different protocols for producing fibrils from recPrP or PrPC in vitro have 
been developed by several groups. In contrast to yeast prions in which the 
amyloidogenic regions are natively unfolded, the PrP domain associated with 
mammalian prion infectivity is structured and thermodynamically stable [169].  
Initial studies using recPrP  suggested that the conversion of PrPC to PrPSc requires the 
reduction of the disulfide bridge that connects residues Cys179 and Cys214 and that 
the conversion occurs via a soluble β−sheet monomer. However this conversion does 
not necessarily bring to an infective form although it can form a β-rich isoform and 
consequently fibrils [170]. Moreover, it has been recently shown that, the recMoPrP can 
be folded either to its native, monomeric α-helical isoform or to a β-sheet rich, 
 44 
oligomeric form with the folding regulated by kinetic control [162, 171]. In addition, it has 
been shown that an equilibrium between the α-helical and the β-sheet-rich isoforms, 
where partially denaturing conditions (acidic pH and urea) and with increased 
concentrations of PrP, favors the conversion to the β-oligomer. Interestingly, whilst both 
abnormal isoforms, the β-oligomer and the amyloid form, coexist at pH 4–6 [172], the 
formation of the β-oligomer is favored at pH below 5.5, whereas optimal pH for the 
conversion into amyloid fibrils is between 5 and 7 [172].  
Further still, the conversion to β-sheet of recPrP is strongly dependent on pH, 
denaturant concentration, and the presence of salts [166, 173]. 
Because chemical denaturants and elevated temperatures are the most common ways 
to manipulate the dynamic balance between different unfolding intermediate states, it is 
not surprising that the first experimental protocols for producing amyloid fibrils from the 
structured C-terminal domain of α-recPrP (recPrP(90–231)) utilized partially denaturing 
conditions, such as chemical denaturants [170] [174, 175] or combinations of elevated 
temperature and high pressure [176]. Moreover, detailed studies of the effect of the 
denatured agent used have shown how the concentration and the type of agent 
denaturant can affect the rate and the state of the PrP protein. In 0.4 M urea and at 
37°C, the protein maintains its native state [166].  
As no unique protocol for making fibrils exist, modifications have been made, which are 
dependent on the aim of the scientist making the fibrils. Most studies have used the 
truncated form of recPrP [166]. Although recently a protocol to produce fibrils from full-
length PrP has recently been developed. [174]. These protocols evolved around using 
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the same conditions for amyloid formation that was used when the first synthetic prions 
were produced (MoSP1) [174, 177]. 
An alternative to the system above, Riesner and co-workers have established an 
alternative conversion procedure, where amyloid fibrils are produced by incubating 
recPrP(90– 231) or PrPC in the presence of low concentrations of sodium dodecyl 
sulfate (SDS) or in the presence of lipids [178, 179]. 
Cell free conversion studies have demonstrated similar findings to studies in vivo upon 
the role of PrP to the transmission and the pathogenesis of TSE. The work of Kaneko et 
al. with labeled PrPC demonstrated a high specificity in the PrPC to PrPSc conversion 
[180]. Using a similar approach, Bossers et al. have shown that the nature of PrPSc has 
an impact on the yield of the conversion reaction [181]. In contrast, evidence exists that 
suggest that the complete disaggregation and denaturation of PrPSc in the presence of 
high concentrations of denaturant abolishes the conversion, whereas unfolding of PrPC 
has no influence on the converting activity [180].  
In order to explain the mechanism by which a misfolded form of PrP could induce the 
refolding of native, normal PrP molecules into the abnormal conformation, two distinct 
models have been postulated: (A) the template assistance or 'refolding' model, and (B) 
the nucleation-polymerization or 'seeding' model (Fig. 13). 
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Fig. 13. Proposed models of prion replication. A: In the template-directed refolding model, PrPSc is not 
normally present in the brain and its spontaneous formation is impeded by a large energy barrier between 
PrPC and PrPSc. Exogenous PrPSc recruits host PrPC and templates its conversion to an additional copy of 
PrPSc. Amyloid formation is a byproduct of prion replication and does not figure explicitly in the 
mechanism. B: In the seeded nucleation model, an equilibrium exists in the brain between PrPC and 
PrPSc (although the balance is shifted greatly towards PrPC). The formation of a PrPSc seed occurs slowly 
and is favoured by the introduction of exogenous PrPSc. Once the seed has formed, recruitment of 
additional PrPSc occurs rapidly allowing the formation of larger amyloids. Fragmentation of amyloid into 
smaller pieces generates new seeds and allows prion replication to progress (Figure modify from [182]). 
 
The first model postulates an interaction between exogenously introduced PrPSc and 
endogenous PrPC, which is induced to transform itself into further PrPSc. A high-energy 
barrier may prevent spontaneous conversion of PrPC and PrPSc at detectable rates 
[183]. This reaction may involve extensive unfolding and refolding of the protein to 
explain the postulated high-energy barrier and could be dependent on an enzyme or 
chaperone, provisionally designated as protein X [84]. In the second model, i.e. the 
nucleation model, PrPC and PrPSc are in an equilibrium strongly favoring PrPC [184], 
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[185]. Only if several monomeric PrPSc molecules are mounted into a highly ordered 
seed, can further monomeric PrPSc be recruited which will eventually aggregate to form 
amyloid assemblys. Within such a crystal-like seed, PrPSc becomes stabilized. 
Furthermore, fragmentation of PrPSc aggregates increase the number of nuclei, which 
can recruit further PrPSc molecules and thus result in apparent replication of the agent. 
Consistent with the latter model, cell-free conversion studies indicate that PrPSc 
aggregates are able to convert PrPC into a protease-resistant PrP isoform [180, 186]. 
Moreover, this model postulates that small amounts of PrPSc are present in a healthy 
brain. Supporting this idea, PrPres has been shown to be amplified from control healthy 
brain samples using the protein misfolding cyclic amplification (PMCA) procedure [187]. 
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Synthetic mammalian prions 
The most stringent criteria for judging whether prion infectivity is generated in vitro de 
novo are the bioassay in animals. Recently, it was shown that the transmissible form of 
prion disease could be induced in transgenic (Tg) mice that expressed PrP(89–231) at 
high levels (Tg9949) by inoculation with amyloid fibrils generated in vitro from 
MoPrP(89–230) [87]. However, these fibrils did not cause disease up-to 600 days after 
the inoculation into wild type mice. Most interestingly, after the first passage in Tg9949, 
the synthetic prions were transmitted to both Tg9949 and to wild type animals in the 
second passage [87]. 
Similar to the fibrils formed from recPrP(89–230), a chemically synthesized 55-residue 
peptide (residues 90 to 145) harboring a P101L mutation and refolded in vitro into a β-
conformation was shown to induce disease in transgenic mice that express PrP(P101L) 
[180]. In contrast to the Tg9949 mice, the TgPrP(P101L) mice were found to develop 
disease spontaneously, even in the absence of the synthetic peptide [188]. On the other 
hand, Tg9949 mice did not develop any clinical signs of spontaneous disease, nor did 
they produce transmissible scrapie upon aging.  
With regards to biochemical and neuropathological features, the two studies showed 
different findings. In the Tg9949 mice which had been inoculated with fibrils a novel 
strain of TSE were discovered [189]. Whereas the disease associated PrP conformer 
identified in TgPrP(P101L) mice and inoculated with the synthetic 55-residue peptide, 
the conformation of the protein was indistinguishable from that seen in the same Tg 
mice that developed disease spontaneously [190]. Taken together these data argue, 
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that the 55-residue peptide accelerated a slowly progressing, spontaneous form of the 
disease, whereas the fibrils of recPrP(89–230) caused prion disease de novo.  
Perplexing though was that the incubation times observed upon inoculation of fibrillar 
MoPrP(89–230) were much longer than those exhibited by most known PrPSc strains. 
Because the length of incubation time is typically used as a measure of prion infectivity 
titer, this assay brought to the hasty conclusion that synthetic prions would exhibit a 
very low infectivity titer. However, this conclusion cannot be accepted because the 
infectivity of natural TSE strains has been tested only on a particular host and not all 
strains. Based on the knowledge of the molecular mechanism of prion conversion, Soto 
et al. developed the PMCA technology (Fig. 14), designed to mimic PrPSc autocatalytic 
replication in vitro [191]. In a cyclic manner, minute quantities of PrPSc (as little as one 
single particle) induce misfolding of large amounts of PrPC in a process catalyzed by 
ultrasound waves to multiply the number of converting units. Moreover, they recently 
demonstrated that it is possible to produce a synthetic PrP from the PMCA and observe 
directly an effect in wild type mice. Whilst this finding has high importance there are 
technical issues to consider, such as whether another molecule besides PrPSc could 
have been enriched in the process of PMCA that caused the effect [192]. 
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Fig. 14. Schematic representation of methodologies used to produce synthetic prions using 
purified substrates. A: Schematic diagram of the production of new synthetic prions using the PMCA 
method by serial dilution and propagation of PrPSc starting by purified PrPC [193]. B: Schematic 
representation of the procedure for the production of synthetic prion without use a seeding of PrPSc with 
changes in the condition of PMCA for mimic sporadic condition. C: Schematic representation of the 
procedure for production of the first synthetic prion using recPrP [87]. 
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In vitro assay for the infectivity 
Conversion of PrPC to PrPSc has been successfully reproduced in cell-based and animal 
systems in which PrPSc is propagated and prion infectivity is maintained. As mentioned 
in the previous section, several in vitro conversion assays have been introduced over 
the past 15 years to investigate how PrPC is conformationally altered by PrPSc.  
However, molecular conversion, in various cell-free systems have failed to completely 
reproduce the proposed prion conversion process. Although close, none of the in vitro 
systems simulate perfectly prion propagation. Conversion of PrPC to PrPSc seems to be 
difficult in most cell-free reactions unless other molecules besides PrP isoforms are also 
present. The continuous evolution of in vitro assays mimicking the conditions of prion 
conversion and propagation is still under progress. 
Table 1 gives a summary all currently used in vitro conversion assay systems. 
The most recently developed system is the so-called amyloid seeding assay (ASA) 
developed by Colby et al. [194] (Table 1). The assay can detect the infectivity in 
biological sample. Furthermore, the assay shows that many prion strains are capable of 
seeding the polymerization of recPrP into amyloid, and that property of each strain can 
be used as a means for the detection of prions in biological samples [194]. 
In terms of data, the quickening of the kinetic profile indicates the presence of infective 
molecule. Taking into account the capabilities of this assay, it is one of the fastest and 
most reproducible protocols to use. 
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Table1. Summary of in vitro conversion assay develop in prion field. 
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Current structural models for PrPSc 
As the structure of PrPSc is still elusive because of its insoluble nature and because is 
inaccessible to conventional methods of protein structural biology, such as NMR 
spectroscopy or X-ray crystallography, alternative combination of methodologies have 
been utilized to produce structural data. In 2002, Wille et al. used electron microscopy in 
combination with computational imaging and modeling methods, to study the structure 
of two-dimensional crystals of PrP27-30, and produce from the reconstructed images, a 
model showing that the repetitive unit of the crystals had hexagonal symmetry [195]. 
Assuming PrPSc has a similar structure to currently known proteins, the authors 
suggested that the hexagonal symmetry came from a trimeric structure, and proposed a 
“left handed β–helical model,” as shown in Fig. 15 [196]. 
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Fig. 15. Model of PrPSc. Left handed β–helical model [196] A: The -helical model of the N-terminal part of 
PrP 27–30 B: Model of the monomer of PrP 27–30. The -helical region (residues 177–227) as determined 
by NMR spectroscopy (PDB ID code 1QM0 [PDB]) was linked to the -helical model shown in A. C: The 
crystal structure of the trimeric carbonic anhydrase from Methanosarcina thermophila (PDB ID code 1THJ 
[PDB]). D: Trimeric model of PrP 27–30 built by superimposing three monomeric models onto the 
coordinates of the C 's of the 1THJ [PDB] structure. 
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In their model, the N-terminus of each monomeric subunit (residues 89-175) forms left-
handed β-helices in the core part of the trimer, whereas the C-terminus (residues 176-
227) largely preserves the disulfide-linked α helices at the outer part with the glycosyl 
groups pointing away from the center. The structures proposed are highly regular and 
repetitive, and symmetrical fold formed by the coiling of elongated β–sheets into helical 
‘rungs’. Left-handed β-helices are stacks of triangular rungs that typically incorporate 18 
residues per rung. This model is derived directly from the experimental electron 
crystallography data, which clearly show the circular-elliptical form. DeMarco and 
Daggett utilized molecular dynamics to simulate PrP conversion, which resulted in 
another theoretical model being proposed, the “spiral model”, as shown in Fig. 16 [197]. 
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Fig. 16. The spiral model A: Building of a protofibril with 31 axis (viewed down the fiber axis). The 
oligomerization site occurs between the isolated strand and a three-stranded sheet of the adjacent 
monomer. B: Views of hexameric representation of protofibril showing maintenance of symmetry on 
oligomerization and propagation of the extended strands between monomers to form extended sheets 
(from [197]). 
 
In this model, each monomeric subunit in PrPSc preserves all three α-helices, but has 
increased β-sheet content in the 116-164 region, consisting of a three-stranded sheet 
and one isolated strand. During polymerization, each isolated strand is connected with 
the adjacent monomer’s three-stranded sheet to form a continuous four-stranded sheet, 
which leads to a spiraling protofibril. This model was developed targeting the dimension 
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of a small aggregate studied by EM. The minimum and maximum diameters, excluding 
glycans of the spiral model are 58 Â [195]. 
In 1994, Reed Wickner proposed that two non-Mendelian genetic elements of yeast 
Saccharomyces cerevisiae, [PSI+] and [URE3], were also caused by a self-propagating 
conformational conversion of protein [198], which extended the prion concept from the 
infectious agent of TSEs to heritable elements in yeast. To date, six prions in yeast and 
other fungi have been identified [199]. Although fungal prions do not share amino acid 
sequence identity with mammalian PrP, these fungal proteins display prion-like 
mechanisms of propagation. The aggregation of soluble fungal prion proteins into 
amyloid fibrils changes the phenotype of cells, and these characteristics can be 
cytoplasmically transferred from mother to daughter cell, showing that the altered 
phenotype is heritable. Studies on these fungal prions have been proven extremely 
valuable [200]. For example, one of the best-studied fungal prion, the translation 
termination factor Sup35p, can aggregate into distinct forms of amyloid fibrils in vitro 
under different experimental conditions [201]. Infection of normal yeast cells with these 
distinct amyloid fibrils was found to generate different [PSI+] strains, providing an 
opportunity to understand the molecular basis of this phenomenon [202].  
HET-s is the prion of the yeast Podospora anserina and is involved in heterokaryon 
incompatibility, a mechanism that controls vegetative cell fusion [203]. Up until recently, 
the only known high-resolution amyloid fibril structure has been obtained by magic-
angle spinning (MAS) NMR spectroscopy on fibrils formed by the prion domain of HET-
s consisting of the C-terminal residues 218-289 [204, 205]. 
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An earlier study, proposed that the β-strand regions were derived from proton-deuterium 
exchange experiments and solid state MAS NMR chemical shifts [206]. In contrast to 
other MAS NMR studies of amyloid fibrils, the observed lines are very narrow. 
Interestingly, in CP-MAS spectra only 43 of the 78 residues were detected [207, 208]. 
Most of the missing residues were, however, observed using proton detection and 
solution NMR techniques, indicating a high mobility in some parts of the protein [207]. In 
addition, the observed chemical shifts suggest a random coil conformation of these 
residues which comprise the N and C-terminus of the protein and residues in the loop 
regions. 
Now, high resolution structures for HET-s(218-289) have been presented [205]. The 
monomeric unit forms eight short β-strands. Six of them are arranged in a manner 
similar to a left-handed β-helix or β-solenoid with two coils per monomeric unit, Fig. 17. 
Thereby, the β-strands incorporated in the same β-sheet are pseudo repeats of each 
other. Between strands three and four a long loop region, not incorporated in the fibril 
core, is observed. 
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Fig. 17. Representations of the high resolution MAS NMR structure of HET-s(218-289). A: backbone 
fold of five monomeric units, the single monomeric units are shown in different colours, B: structural 
ensemble of a monomeric unit. From [205]. 
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Aim of this work 
Despite considerable research efforts, the mechanism by which the PrP converts into 
the pathological abnormal form remains enigmatic. Whilst people have begun to show 
that is it possible to produce the infectious molecule in the test tube no clear evidence 
exists for the structure of this molecule. Solubility problems and the reproducibility of the 
preparation of the fibers are still outstanting problems.  
The major aim of this study has involved a systematic analysis of the different 
conditions under which fibrils can be formed, with the ultimate aim to produce a 
reproducible protocol to use for biochemical and biophysical studies.  
As a starting point, my project commenced, using other proteins; α-synuclein, β protein, 
insulin, in order to learn the commonalities of the methodologies to produce fibers and 
further improve the approach and understanding of aggregation studies, in particular to 
that of PrP.  
For the production of fibrils from the PrP, I have analyzed in great details the effects of 
changes in the environmental conditions on the morphology of the fibrils, with particular 
attention to the conditions, which appear to aid in demonstrating the presence of an 
infective molecule. 
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Chapter 3: Materials and Methods 
 
Preparation of recPrP 
The recMoPrP(89-230) was a kind gift of the Prusiner laboratory, University of California 
at San Francisco, San Francisco, USA [163]. 
 
Monitoring of the kinetics of in vitro amyloid formation 
To monitor the formation of amyloid fibrils in our samples, lyophilized recMoPrP(89-230) 
was initially dissolved in 6 M GndHCl, to a protein concentration of 1-5 mg/mL. The 
aliquots were kept frozen at -80°C until used. Upon use, the stock protein solution was 
made to a final protein concentration of 50 µg/mL. This was then incubated in 1X PBS 
buffer pH 7, 10 µM thioflavin T (ThT) with different concentrations of guanidinium 
hydrochloride (GdnHCl) (0.4 M to 4 M) in a reaction volume of 200 µL in 96-well plates 
(BD Falcon 353945, BD Bioscience).  
For the seeding experiments, which were performed to provide information as regards 
to the autocatalytic nature of the reaction, small amounts of preformed aggregates were 
added to the reaction mixture at t=0. To each well, 4 µL of the seeding sample was 
added to the 200 µL reaction. To the seeding experiments, a glass bead was also 
added to each well, to increase the production of the kinetic profile. The 96-well plate 
was covered with sealing tape (Perkin Elmer) and incubated at 37°C with continuous 
shaking on a plate reader (Spectramax M5 and Gemini EM, Molecular device). The 
kinetic of fibril formation was monitored by top reading of the fluorescence intensity 
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every 5 min, using 444 nm excitation and 485 nm emission filters. Each sample was 
measured in six independent replicates and the differences were evaluated using 
statistic programs R software. Data were assessed using different methodologies: one 
was based on [209], the other was based on a qualitative evaluation. The analysis was 
performed using a R program to verify any statistical differences (See Appendix for 
mathematical approach).  
 
Dynamic Light Scattering 
Dynamic light scattering (DLS) was used to analyse the homogeneity of the fibril 
formation. To this aim a dynamic light scattering with DLS Zeta sizer Nano zs Malvern 
(Dispersion Technology Software) was used. After the fibrillization reaction, samples 
were analysed after dialysis with phosphate buffer. The analysis was performed at the 
same concentration of the protein, and verified by calculations using the extinction 
coefficient. 
 
Phosphotungstic acid (PTA) precipitation of PrPSc from ScGT1 cell 
lysates 
GT1 and ScGT1 cells were grown in DMEM containing 10% fetal bovine serum and 1% 
penicillin/streptomycin at 37°C and 5% CO2. Cells were split 1:10, incubated for 7 days 
and then disrupted using lysis buffer (10 mM Tris HCl pH 8, 150 mM NaCl, 0.5 % NP-
40, 0.5 % DOC). Typically, total protein concentration of 1 mg/mL was used for the PTA 
protocol as described by Colby et al. 2008. PTA from a 10% (wt/vol) stock solution (pH 
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7.4) was added to the sample to a final concentration of 0.5%. Then, it was incubated 
the sample with constant shaking (350 rpm) for 1 h at 37°C. After incubation, samples 
were centrifuged at 14,000 g for 30 min at room temperature (RT). The pellet were 
washed with 500 µL of PBS/2% sarkosyl, containing protease inhibitors, and centrifuged 
at 14,000 × g for 30 min at RT. The pellet was resuspended in 150 µL of water and then 
stored it at −80°C until use. 
 
 Amyloid Seeding Assay (ASA) 
Briefly, total cells extracted in sarkosyl were precipitated with PTA to purify prions. Four 
µL of PTA purified brain cell extracted were diluted into 400 µL water, then used as 
seeds in amyloid formation reactions. A 96-well plate was prepared with 180 µL/well of 
MoPrP(89-230) solution (50 µg/mL recMoPrP(89–230), 0.4 M GdnHCl, 1XPBS, 10 µM 
ThT). Twenty µL of diluted PTA-precipitated brain homogenate were added to each 
well, with each sample tested with six replicates. ThT fluorescence measurements were 
taken at 444/485 nm excitation/emission spectra on a Spectramax M5 fluorescence 
plate reader with continuous shaking at 37°C. 
 
Atomic Force Microscopy (AFM) 
MoPrP(89-230) solutions prepared with different GdnHCl molarities were deposited 
evenly onto a freshly cleaved piece of mica at a concentration of 50 µg/mL, and left to 
adhere for 1-10 mins. Samples were then washed with distilled water and dried with N2. 
Specimen were imaged with a NanoWizard-II BioAFM (JPK Instruments AG, Berlin, 
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Germany, www.jpk.com) operating in dynamic mode and using non-contact cantilevers 
(NSG11, NT-MDT – Moscow, Russia, www.ntmdt.com or ARROW-NCR, NanoWorld-
Neuchâtel, Switzerland, www.nanoworld.com) with tip radii of <7-10 nm, spring 
constants of 20-42 N/m, and resonance frequencies of 285-325 kHz.  
The images were acquired at line scan rates of 0.5-1 Hz at RT. 
The images were analyzed using Gwyddion software (http://gwyddion.net/), which 
extracts data from the scanned images and evaluates the statistical value of the image. 
All data was analysed with the R program (http://www.r-project.org/). 
 
Circular dichroism of MoPrP(89-230) at different concentrations of 
GdnHCl 
Circular dichroism (CD) spectra were obtained with a JASCO J-810 spectrometer at 
20°C in 20 mM Na-Phosphate pH 7. Far-UV CD spectra (208-250 nm) were recorded at 
protein concentrations of 0.2 mg/mL in a 0.1 cm cell, with an average of 6 accumulated 
scans, and at varying GdnHCl concentrations. 
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Chapter 4: Results 
The kinetics and the products from in vitro fibril formation assay are 
affected by the concentration of the denaturant used 
In order to gain insight into the physical properties that separate infectious from 
noninfectious MoPrP(89-230) fibrils, the kinetics of fibril formation was analyzed in 
greater detail. It is known that the addition of GdnHCl improves the yield and shortens 
the lag phase of fibril formation, but is also influential in physical properties of the fibrils 
[210]. Toward this aim, different concentrations of GdnHCl were employed in the 
fibrilization assay 
Previous studies have shown that in an attempt to generate the infectious PrP forms, 
different strategies have been pursued. There is the PrPSc-dependent conversion or 
amplification [211] [180], [191] and the conversion of PrPC or recPrP in the absence of a 
PrPSc template [212] [172] [170] [173] approach. Moreover, these topics have been 
analyzed in several review papers [213] [212]. 
An alternative approach has more parallels with the sporadic formation of prions, rather 
than with prion diseases acquired through transmission. In opposition to the 
amplification approach, where the physical properties of the newly generated PrPSc are 
expected to mimic that of PrPSc seeds, the conversion reaction in the absence of PrPSc 
seeds poses question as regards to the uncertainty with regarding the conformation of 
the final products of the reaction.  
 66 
By analogy to the studies where the amyloid form has been shown to be equivalent to a 
prion state for several yeast prions [202, 214] and [202, 214-217], converting recPrP 
into amyloid fibrils seems to be one of the possible ways for de novo generation of 
mammalian prion infectivity in vitro. For the last few years several protocols for 
producing fibrils from recPrP or PrPC have been developed by different groups. In 
contrast to yeast prions in which the amyloidogenic regions are natively unfolded, the  
domain associated with mammalian prion infectivity is partially structured and 
thermodynamically stable [169]. Due to the fact that chemical denaturants and elevated 
temperatures are the most common way of manipulating the dynamic balance between 
different unfolding intermediate states, it is not surprising that the first experimental 
protocols for producing amyloid fibrils from the structured Mo(PrP90–231) utilized 
partially denaturing conditions such as chemical denaturants [170], [218], [166], [25], 
[219] and [220] or combinations of elevated temperature and high pressure [176]. 
Amyloid formation can be monitored in solution using the dye ThT [152]. This dye 
undergoes a fluorescence shift upon binding to amyloid fibers, from 342 to 442 nm and 
from 430 to 482 nm for excitation and emission maxima, respectively. As ThT does not 
fluoresce significantly at excitation/emission maxima of 442/482 nm in the absence of 
amyloid fibers, the background signal tends to be quite low, and hence the dye is used 
as highly sensitive reporter. When used in conjunction with multi-well plates and 
automated plate readers that record fluorescence over time, ThT offers ideal solution, of 
detecting conformational changes of proteins in solution.  
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In order to get acquainted with the process of formation of fibrils I started to investigate 
the protocol to form fibrils. There are at least two main different ways to produce fibrils 
using either (a) discontinuous assay or (b) continuous assay (Fig. 18).  
The first procedure is base on the fact the fibrils are made in a pure condition, with the 
kinetic profile of ThT obtained in a discontinuous time. The kinetic profile is obtained by 
numerous readings of the sample at different time points. However, this type of analysis 
gives problems in the reproducibility of kinetic profile, and also depends upon the 
number of time points read and the operator ability. Moreover, the total protein levels 
change during the procedure, thus possibly altering the true kinetic reading. 
 
Fig. 18. Schematic production of fibrils. A: Method for preparing fibrils in a continuous assay. Protein 
is : incubated with the presence of ThT at 37 °C with agitation of 600 rpm. B: Method  for preparing fibrils 
in a discontinous assay. Protein dissolved in particular protein concentration and buffer condition and 
incubatde at 37°C without the presence of the ThT molecule. Aliquots of the solution are taken and read 
on a fluorimeter in the presence of ThT. 
 
The continuous assay first appeared in the literature authored by the laboratory of Ilia 
Baskakov, where they demonstrated the possibility of obtaining a kinetic profile, using a 
plate of 96-well in a plate reader, using a continuous reading without alternating sample 
readings [174]. 
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The results obtained using this procedure gave reliable results. The protein chosen for 
that primary purpose was insulin. I performed fibril formation using a simple protocol 
giving intriguing results. Then we use the discontinuous assay using MoPrP(89-230) in 
1X PBS/2 M GdnHCl pH 7. This protocol is a standard protocol for preparing fibrils for 
many researchs [174, 221]. The kinetic results obtained are summarizes in the Fig. 19. 
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Fig 19. Kinetic profile of MoPrP(89-230) incubated at 37°C with 600 rpm. Here I report time course of 
MoPrP(90-230) conversion in the presence of 2 M GdnHCl. The reaction was monitored by ThT 
fluorescence readings. 
It was observed difference in the rate of fibrilization using both procedure. The lag-
phase starts either at 9-10 hours or at 40 hours or more. For a practically point of view 
for more experiments we use a continuous assay because allow to follow all process 
without interruption. Another important factor of the use of continuous assay is that the 
concentration of the protein in the test tube remains constant throughout the reaction. 
However, the procedure employed in a discontinuous assay has been generally used in 
many paper. Due to the fact the continuous protocol gives better resolution for the 
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reproducibility of fibril formation. The presence of glass beads inside the well plate helps 
to obtain a quite reproducible kinetic profile. 
The reaction is characterized by a well-defined lag phase followed by a growth phase, 
consistent with a nucleation dependent polymerization mechanism. Moreover, the 
conversion seems to be possible even in the presence of high denaturant 
concentrations, conditions under which the protein is fully unfolded. I have performed a 
series of kinetic experiments in which an array of different growth condition were 
employed. The conversion was studied under different experimental conditions and 
special attention was focused on the influence of denaturants on the conversion 
mechanism and the morphology of the conversion products. The experiments were 
performed under vigorous shaking conditions at pH 7, and 37°C. The typical fibril 
formation process starts with a lag phase in which the amount of amyloid proteins 
turned into of fibrils is not significant enough to be detected. Afterwards, a drastic 
elongation phase follows and fibril concentration increase rapidly (see figure below). 
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Fig. 20. Kinetic profiles of fibril formation in 96-well by continuous assay. Example of the kinetic 
profile made by change the concentration of guanidine inside the growth condition. From the right to the 
left it was possible to observed the decrease of the lag phase. 
 
Low concentration of GdnHCl in solution gives a relative long lag-phase in contrast to 
high concentration of that denaturant. Above 1M of GdnHCl It was obtained quite the 
same lag-phase (Fig. 20). These results is in agreement what was found by other 
authors but contradicts what some author believe that high concentration of GdnHCl 
increase the lag-phase time [166]. 
The kinetic data profiles were analyzed using a mathematical approach for calculate the 
lag-phase value (see Appendix I: Mathematical approach). 
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Due to the fact recently demonstrated that it is possible to amplify many different prion 
strains by using a particular concentration of GdnHCl I wanted to analyze in detail the 
effect of different concentration to the fibril formation. The results support the fact of the 
reliability of the continuous assay and the in vitro approach. 
The studies were focused only on two concentrations of denaturant: 2 M GdnHCl and 
0.4 M GdnHCl. The first concentration of GdnHCl was already used in many 
publications by other authors, which gave good results in terms of fibril formation. The 
second concentration was chosen because this particular concentration gave a read out 
of the infectivity. Thus, these concentrations were used in discontinuous growth 
condition [222], [65], [174]. 
The kinetic profiles extracted by these two concentrations follow the same sigmoidal 
kinetic curve typical of an aggregation of the protein, which was clearly different 
between the two preparations (Fig. 21). This kinetic difference was observed in all 
experimental assay runs. 
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Fig. 21. A: Time course of MoPrP(89-230) conversion in the presence of 2 M GdnHCl (solid line) and 0.4 
M GdnHCl (dotted line). The curves results are shown as mean of different kinetic curves. B: Mean value 
of the lag-phase for the two different solvent conditions (2 M and 0.4 M GdnHCl) as calculated using the 
equation of quadratic and exponential functions Bishop-Ferrone [209]. Bars denote the standard error 
(n=6; *, p <0.01; **, p<0.05; ***, p< 0.001). 
 
It was observed that the mean lag phase of 2 M GdnHCl condition gave a fast kinetic 
profile than 0.4 M GdnHCl. ANOVAs analysis shows statistically significant difference 
each growth condition (p <0.001). 
Using different estimation protocol we obtain the same ratio of difference between 
growth conditions as reported in Table 2 below. 
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Concentration of 
GdnHCl 
 
Bishop and Ferrone 
[209] 
 
Cohlberg et al. 
[223] 
Qualitatively 
 
 
2 M GdnHCl (n=106) 4.155±0.166 5.22±0.160 4.67±0.160 
0.4 M GdnHCl (n=68) 9.72±0.487 10.8±0.495 12.11±0.523 
 
Table 2. Lag-phase values estimated using a script in R program as describe AppendixI:Mathematical 
approach. 
 
In addition the maximum ThT fluorescence intensities also showed differences between 
the two preparations. The preparation using 2 M GdnHCl appeared to show a trimodal 
probability density distribution. In contrast, the preparation with 0.4 M GdnHCl revealed 
a different probability density distribution (data not shown). With this preparation the 
probability of the maximum intensity of ThT signal was higher in the lower signal 
intensities compared to what was found with the 2 M GdnHCl preparation (Fig. 22).  
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Fig. 22. Mean value of ThT max Intensity in two different solvent conditions(2 M and 0.4 M GdnHCl) as 
calculated from data before normalization by script run R programs (http://www.r-project.org/). 
 
Furthermore, in the 2 M GdnHCl preparation, a non zero probability density at the 
higher signal levels was present, which was different from that of 0.4 M GdnHCl. These 
results suggest that the mechanism, which we used to detect the aggregation process, 
reveals a different mechanism of fluorescence in terms of intensity between the growth 
conditions (data not shown). 
Changing the concentration of GdnHCl from 2 to 0.4 M revealed an extension of the lag 
phase (Fig. 21B). This difference in the kinetic trace and the maximum intensity 
frequency (Fig. 22) was also showed by the differences in the morphology of the 
aggregates as revealed by AFM (Fig. 26 A-B). 
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Kinetics of fibril formation is accelerated by seeding 
MoPrP(89–230) formed amyloid in the presence of low concentrations of GdnHCl, as 
measured by ThT fluorescence (Fig. 22). When preformed fibers of MoPrP(89–230) 
were added to the reaction, amyloid formed much more rapidly. This phenomenon is 
defined seeding effect. The presence of seeds in an amyloid formation reaction was 
quantitatively detected either by observing a decrease in the mean lag phase of the 
reaction compared to control samples, or by observing an increase in the mean ThT 
signal during the period before negative control samples began to polymerize. 
During our analysis of both conditions, we additionally tried to analyze the effects of 
seeding using different solvent condition. I tested the effect of cross seeding in both 
solvent conditions and observed a general universal effect of seeding as in agreement 
with many studies [224], [184], [90], but our data cast light on some differences related 
to the reaction rate. Homo-seeding was more efficient than the cross seeding in both 
protocols, which is in agreement with previous studies using full length prion protein for 
the preparation [210]. In the 0.4 M GdnHCl preparation, fibrils made in 2 M GdnHCl 
condition had only a small seeding effect although they showed a high effect of seeding 
in 2 M of GdnHCl (Fig. 23). 
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Fig. 23. Effect of seeding of MoPrP(89.230). A: Change in lag phase mean values after seeding 0.4 M 
GdnHCl. B: Change in lag phase mean values after seeding in 2 M.  
 
Seeding effect was seen in all samples. The seeding effect of homogeneous solution in 
both cases resulted in a decrease of the lag phase (Fig. 23). This was a more apparent 
decrease for the 0.4 M GdnHCl preparation and more efficient compared to 2 M 
GdnHCl suggesting that the length of the lag phase could be a key for detecting 
different prion strains. Probably for this reason 0.4 M GdnHCl was chose as base on the 
Colby et al. protocol.  
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Atomic force microscopy analysis of end products 
The atomic force microscope (AFM) or scanning force microscope (SFM) are very high-
resolution type of scanning probe microscopies, with demonstrated resolution of 
fractions of a nanometer, more than 1000 times better than the optical diffraction limit. 
The AFM has several advantages: unlike the electron microscope, which provides a 
two-dimensional projection or a two-dimensional image of a sample, the AFM provides 
a true three-dimensional surface profile. Additionally, samples viewed by AFM do not 
require any special treatments (such as metal/carbon coatings) that would irreversibly 
change or damage the sample. Disadvantages of AFM are the image size and an 
incorrect choice of tip can lead to image artifacts. 
To gain further insight into the structures of the aggregate products in both preparations, 
we studied their topology using AFM in ambient conditions. The preparations were 
viewed at the end-point of growth using recombinant MoPrP(89-230) synthesis in vitro 
for both aggregation conditions and revealed different substructure data. Furthermore, 
Imaging of the samples confirmed that highly polymorphic fibrils form in a single growth 
condition as described in the literature [225].  
The MoPrP(89-230) incubate at 2 M GdnHCl by discontinuous assay was analyzed by 
AFM show fibril formation. In the first time it was observed a low yield but after improve 
the manual ability increase the yield of fibrils aggregates. 
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The scanning was performed in different substrate like mica, glass and silica surface. 
What was evident the mica is a system more rapidly for analysis the fibrils in AFM as 
described by Anderson et al. [226]. 
 
 
Fig. 24. MoPrP(89-230) fibril preparation in discontinuous assay. A: Topography of the fibrils. B: 
Topography of one fibrils were was perform the height profile reported in C. C: Distribution of height long 
x axes of one fibril. 
 
In Fig 24 A and B, AFM scans of mica surfaces prepared in discontinuous protocol gave 
a typical fibril morphology. Comparison of the data obtained by our readings with the 
other author they approach these problems, shows the same polymorphic structure 
[226]. The length of the fibrils made by discontinuous assay was up to 2 µm. 
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Fig. 25. AFM scan topographical images of PrP deposited mica surfaces made by discontinuous 
assay. 5x5 µm area was scan acquired by AFM (1024x207 pixel). 
 
Due to the fact we want to characterize the structure of different growth condition we 
perform many scanning in the sample prepared in the two growth conditions. 
The kinetic profile clearly shows difference between two growth conditions. In fact the 
kinetic profile have a different rate but also the intensity of ThT is different. These 
differences are due to a different assembly of the aggregates as show by analysis of the 
AFM scans.  
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Fig. 26. AFM imaging was performed at the end of the fibrillation reactions. The reaction was formed 
in two solvent conditions 0.4 M GdnHCl (A) and 2 M GdnHCl (B). Scale bars represent 500 nm as 
depicted. 
 
In Fig. 26 A and B, AFM scans of mica surfaces prepared with these solutions clearly 
revealed differences in the two growth conditions of the preparations. The solution with 
the concentration of0.4 M GdnHCl contained a few nanometer sized, mostly globular, 
aggregates of the protein in addition to a small number of short fibril fragments with less 
than 100 nm length. In contrast, the high concentration of denaturant (2 M GdnHCl) 
solution showed long amyloid fibrils of the protein in addition to a few smaller fibril 
fragments. Preparation with 2 M GdnHCl resulted in the formation of fully mature fibrils. 
The major fibrillar subtypes were either straight or slightly curvy ribbons or rod-shape 
fibrils, which is in agreement with earlier studies using the same concentration of 
chaotropic agent, but in a different buffer solutions (Fig. 26F A-B). 
The distribution of fibril height in the profiles from both preparations gave differing 
results (Fig. 27 A-B). The deconvolved line profiles from the blind estimated tip shape 
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suggested an approximate 5 nm FWHM width of the fibril (data not shown). AFM  
cannot provide a high precision results about the width of the fibrils because of an effect 
know as tip convolution. The AFM tip radi are usually about 5-6 times wider than the 
fibrillar structures. 
 
Fig. 27. A 3D representations of the AFM topography images as in Fig. 26. B: Height distribution data 
obtained from the AFM images in part A. An exponential curve for the low topographical structures was 
subtracted from the data. The frequency peaks at the levels of 3.2 nm, 5.7 nm and 8 nm are marked by 
arrows, suggesting an approximate 2.7 nm periodicity in height. The 3-D views revealed structures with 
different topology (Fig. 27 A-B). Moreover, the frequency peaks height distribution obtained from the 
Gaussian fits indicated the differences. 
 
 
The preparation of 2 M GdnHCl gave a peak of the height at 5.7 nm and 8 nm whereas 
the preparation with 0.4 M GdnHCl revealed peak height levels at 3.2 nm and 5.7 nm. 
The height distribution associated with 5.7 nm is the common height peak found in the 
two preparations, and is probably due to the formation of some protofibrillar structures. 
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Fig. 28. A: 10 mm × 10 mm AFM topographical image of PrP deposited mica surface prepared with 2 M 
GdnHCl. B: A 3 mm × 3 mm higher resolution scan image belonging to the area marked with a blue 
dashed square in part A. C: A 0.75 mm × 1.5 mm higher resolution scan image belonging to the area 
marked with a blue dashed square in part B. D: Topography and phase images of an amyloid fibril 
acquired by AFM.  
 
The length of the fibrils obtained with 2 M GdnHCl could be as long as 1800 nm and 
were composed of straight ribbon-like fibrils, curvy fibrils, and fibrils with occasional 
branching (Fig. 28 A-C). Moreover, the acquired phase image of an amyloid fibril as 
seen in Fig. 28D illustrated that protofilaments were formed with different fragment 
lengths. 
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Detailed analysis of the fragment size is 0.0859±0.00519 µm length. However the 
dimension is not always the same there is a variation.  
In Fig. 29 show different profile shape for both condition: 2 M show a profile typical in 
fibrils while the 0.4 M GdnHCl gave typical dimension of spherical shape with a height 
not more than 5 nm. At the low molarity (0.4 M GdnHCl) preparation, clusters of 
aggregates ~5-6 nm height were seen. In contrast, the 2 M GdnHCl preparations, as 
revealed from the profiles “steps”, featured the height profiles ranging between 3 nm to 
15 nm (measured from the 2 nm baseline) with approximately 4 nm unit height steps 
(Fig. 29).The detail in the branching and fragment formation was observed as shown in 
Fig. 30. 
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Fig. 29. A: AFM scan topographical images of PrP deposited mica surfaces. The PrP is prepared with 0.4 
M GdnHCl (left image) and 2 M GdnHCl concentrations (right image). The white bars show the 
unidirectional length scale. The color scale of the height is given in far right. On the left image isolated 
clusters of PrP oligomers, on the right image amyloid fibrils of PrP are clearly observed. The white 
dashed arrows designate discontinuities along a fibril. B: The AFM height profiles along the blue lines in 
topographical images of part A. The profiles belong to the lines as numbered in the images. 
 
From the analysis of both AFM and kinetics data it can be stated that the solvent 
conditions are a determinant of the final products of the assay. 
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Fig. 30. Dynamic mode AFM scans of an amyloid PrP fibril. A: The height image. B: The phase 
image. The white arrows indicate the points of presumable fragmentation in both of the images. C: Height 
profiles along the lines as color designated and numbered in the height image. The height along the fibril 
lies between 3 nm to 18 nm (measured from the 2 nm baseline) with approximately 3 nm unit height steps 
(see also Fig. 29B). 
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Amyloid Seeding Assay (ASA) from partial purificated PrPSc  
The amyloid seeding assay (ASA) is an alternative protocol for measuring PrPSc in 
biological samples. The ASA employs PTA precipitation, similar to the conformational –
dependent immunoassay (or commonly known as CDI) [9], but detects prions based on 
their propensity to hasten the formation of PrP amyloid rather than detection using 
antibodies. It was found that many prions strains could be detected using the ASA [194]. 
In our study, the ASA protocol appeared to be related to the formation of a particular 
assembly of the aggregates not exhibiting long fibrils. Moreover, our analysis revealed 
how this powerful tool to detect a small quantity of prions, could be associated to the 
different states of the PrP amyloid. The original ASA protocol condition, 0.4 M GdnHCl 
gave a better detection in the assay compared to 2 M GdnHCl. The lag phase after the 
addition of scrapie sample as a seed can be seen in Fig. 31.  
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Fig. 31. The ASA assay using PTA from either GT1 or ScGT1 cells. A: Effect of seeding of PTA 
precipitated of ScGT1 cells using recPrP in the presence of 0.4 M of GdnHCl [194]. B: Effect of seeding 
of PTA precipitated ScGT1 cells using recPrP in the presence of 2 M of GdnHCl . C and D lag phase 
measurements from several experiments using A and B protocols, respectively. 
 
Stability of MoPrP(89-230) was checked also by the effect of the denaturant agent like 
GdnHCl. In order to understand better the performance of the ASA protocol we 
attempeted to perform analysis on the effect of hastening the kinetic curve by extracted 
PTA ScGT1 cells. Increasing the concentration of GdnHCl to the extracted PTA ScGT1 
cells does not block the ability of the extracted PTA samples to hasten the kinetic 
profiles. A titration is presented in Fig. 32. 
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Fig. 32. Effect of increasing GdnHCl concentrations in the ASA protocol. 
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Comparing two different aggregation conditions by CD and 
fluorescence 
We used CD and fluorescence to elucidate the biochemical features that give rise to the 
different aggregated states of recPrP using the two ASA protocols. Guanidinium salts 
are well known for their denaturing action on proteins. In our experiment we use 
GdnHCl, one of the most effective denaturants. In 6 M GndHCl all proteins with an 
ordered structure showed partial or total unfolding and most of them become randomly 
coiled, meaning they do not contain any residual structure. The CD spectral obtained 
from MoPrP(89-230) in different growth conditions are shown in Fig. 33. The CD spectra 
of MoPrP(89-230) in 20 mM sodium phosphate buffer revealed prevalently α-helix 
content in this mixture, without apparent aggregation. Increasing the amounts of 
denaturant changed the conformation of the recombinant protein, which eventually 
became unfolded. The results showed the 0.4 M GdnHCl condition is different from 2 M 
GdnHCl condition of the folded protein. In 2 M GdnHCl we found an increase of random 
coil with respect to 0.4 M GdnHCl. The α-helical content of MoPrP(89-230) without 
denaturant was very similar to that of 0.4 M GdnHCl, as indicated by the intensity of the 
negative maxima at 208 nm and 222 nm (Fig 33). The molecular ellipticity of the 
recombinant protein at 222 nm decreased at increasing concentrations of the 
denaturant. This result suggested that MoPrP(89-230) after dilution during the 
preparation of the working solution in the ASA protocol had the folding of the native 
protein. This may suggest that different concentrations of GdnHCl can lead to different 
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structural conformations. Moreover, the changing of the molar ellipticity intensity could 
be due to the changing of the concentration of GdnHCl.  
 
Fig. 33. A: FarUV CD spectra of MoPrP(89-230) at different concentration of GdnHCl. B: Variation of 
intensity mean ellipticity at 208 nm, 215 nm, 221 nm, 222 nm at different concentrations of GdnHCl. 
 
We also analyzed the variation in the fluorescence of particular aromatic amino acids to 
demonstrate the occurrence of conformational changes. This analysis gives indirect 
information about how the structure differ in solution and during the formation of 
aggregates. In fact, the fluorescence of both preparations was different not only at the 
starting condition, but also at the end of the reaction. The analysis of the intensity ratio 
of 270 nm and 280 nm fluorescence wavelengths showed qualitative differences in two 
conditions. In fact, we found the same solution before performing the aggregation 
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process that the ratio is different between the two growth conditions. These differences 
were also found at the end of the reaction. 
 
 
Fig. 34. Variation in the fluorescence intensity from excitations at 270 nm and 280 nm belonging to 
preparations with 0.4 M and 2 M concentrations of GdnHCl. T = 0 h is the value before starting of the 
fibrilization process at 37C. T = 24 h shows the same after 24 h. 
 
DLS : effect of mechanical agitation using beads on the kinetic of 
fibril formation 
DLS was used to detect the average size of the assembly (Fig. 35). The preparation 
with 2 M GdnHCl resulted in a monodisperse solution, whilst a polydisperse solution 
was observed with the 0.4 M preparation (Fig. 35 A-B). This further supports our 
observations from AFM and kinetics data analyses, i.e. that the two preparations can 
lead to different protein aggregates.  
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Using DLS it was also observed how the size changes in the presence of absence of 
glass beads. These supported the fact the beds help to obtain the select the  size made 
in function of the solvent condition. 
 
Fig. 35. DLS of fibril formation with or without beads using two different concentrations of 
GdnHCl. A: Fibrils sizes using 2 M GdnHCl in the presence of beads. B: Protein aggregates sizes using 
0.4 M GdnHCl in the presence of beads. C: Fibrils sizes using 2 M GdnHCl in the absence of glass 
beads. D: Aggregation size of the protein made using 0.4 M GdnHCl in the absence of glass beads. 
 
The absence of the glass beads gave a polydisperse solution in both buffer conditions. 
However, analysis of 2 M GdnHCl using AFM reveals the presence of much longer 
fibrils than in presence of the beads. However, 0.4 M GdNHCl does not reveal any 
fibrils.  
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Biochemical characterization of fibril assemblies 
PrPSc fibrils produced in vitro by a spontaneous conversion of the recPrP have shorter 
PK-resistant core than those obtained present in brain homogenate with prions. 
Recently, Bocharova et al. reported that the PK-resistant core of Mo and hamster full-
length PrP can be extended to ~16 kDa fragment with the N-terminus at residue 97 
[174, 224, 227]. MoPrP(89-230) protein after fibril preparation was analyzed by SDS-
PAGE and western blotting. No conclusive data were obtained. The result suggests low 
yields of the aggregation preparations for both protocols.  
It was also analyzed the stability of the fibrils at both concentration of GdnHCl. The 
analysis made did not give conclusive results, indicating that there is probably a loss of 
proteins during the analysis.  
 
 94 
 
 
Fig. 36. Wester blots of PK digestion of Mo(PrP89–230) fibrils at two different conditions of 
GdnHCl. The concentration of PK: or the ratio PK:PrP(wt/wt) is indicated on top of each lane. –  or + 
symbols refer to fibrils made in absence or presence of PK, respectively. Western blots were performed 
using the antibody D18. On the left 2 M GdnHCl aggregates using PK resistance and on the right 0.4 M 
GdnHCl. 
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Chapter 5: Discussion 
 
The discovery of prion disease transmission in mammals, as well as a non-Mendelian 
type of inheritance in yeast prions, has led to the establishment of a new concept in 
biology, the prion hypothesis. The prion hypothesis postulates that an abnormal protein 
conformation propagates itself in an autocatalytic manner via recruitment of the normal 
isoform of the same protein as a substrate, and thereby acts as a transmissible agent of 
disease (in mammals). Ironically, while prion researchers have been struggling to 
provide definite proof that the PrP transmits the disease, other amyloidogenic proteins 
have been shown to be able to transmit (or cause) certain neurodegenerative or 
systemic diseases in a prion-like manner [228]. 
In vitro studies are typically performed using pure protein samples or protein in the 
presence of other components found in amyloid deposits. Two aspects of amyloid fibril 
formation can be determined in vitro: i) the structure of the fibril; and ii) the process of 
fibril formation (i.e., the mechanism of kinetics). For both, it is important to first 
characterise the protein using traditional techniques (i.e. SDS-PAGE, DLS, CD, UV-
spectra).  
However, there are caveats and limitations to the study of amyloid fibril formation and 
interpretation of data. The single biggest obstacle in the examination of peptides and 
proteins that can form amyloid fibrils is the preparation of the sample. There have been 
several reports by different laboratories of batch-to-batch variability and poor 
reproducibility of experiments [229]. Several factors can contribute to this variability. 
 96 
One factor to consider is the purity of the peptide or protein sample. Impurities can 
affect the kinetics of aggregation and, unfortunately, there is no way to predict if a 
sample impurity has an effect on aggregation. To reduce chemical degradation of pure 
samples, proper storage conditions are necessary. Typically, peptides are most stable 
when stored -20 or -80°C as a lyophilized powder, under N2, in a desiccator, in the 
freezer. However, even under these conditions, some peptides can undergo chemical 
modifications [230]. 
Another factor affecting sample preparation is the ion-pairing agent used in the 
peptide/protein purification process, since the ion pair can affect the kinetics of 
aggregation. The purification, particularly of peptides, is performed using buffers that 
contain either HCl or trifluoroacetic acid (TFA). Since peptides are charged molecules, 
the negative ion present from the acid (Cl- or TFA-) forms an ion pair with the positively 
charged N-terminus or side chains of the peptide. These two reagents lead to ion pairs 
that differ in size (Cl- <TFA-) and hydrophobicity (Cl- <TFA-) and, consequently, can 
have a significant effect on amyloid fibril formation. The Aβ1–40 peptide, for example, 
has been shown to be random coil by CD if prepared from TFA but β-sheet if purified 
using HCl [231]. Equally, dramatic effects of ion pairing agents on the ability of IAPP24–
29 to form amyloid fibrils have also been reported [230]. However, in relation to this last 
point, as yet, no affect seems to have be reported in the PrP. 
Another caveat which has to be considered that can influence amyloid formation, is the 
effect of agitation, which can affect both the morphology and the kinetic output of the 
fibrils produced. This has been assessed for many proteins [232]. Moreover, recent 
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studies  in the prion field showed the agitation have a big effect on the morphology of 
the fibril formation [233]. The agitation effect is dependent upon the type of machine 
used to produce the agitation and the speed of the agitation. Moreover, physical 
agitation such as shaking could provide an increased kinetic energy for the nucleation 
units to overcome the repelling force between the surface chemical potentials of two 
approaching particles and thus increase. 
For the experiments carried out in this study, the machine used was a Spectramax M5 
(Molecular Devices). No detailed published details exist for this machine and it is 
assumed from communication by technical staff from Molecular Devices, that the 
mechanism of agitation produces in the machine is a step moving by chaotic mixing, 
giving the same centre of agitation and intensity for each well (Fig. 37).  
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Fig. 37. A: Figure depicting two wells with two different concentrations of GdnHCl as used in this study. 
The agitation can be longitudinal, transversal or both. B: Representation of the ratio between the glass 
beads and MoPrP(89-230) The surface glass beads can attract protein due to the charge of the protein. 
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Recently, the development of the ASA has provided a new opportunity to detect prion 
infectivity in biological samples [194]. However, the discovery that prions can be 
artificially created by polymerizing recPrP into amyloid has also led to the development 
of cell-free systems [87]. The ASA assay is based on the availability of prions in 
biological samples, which can be detected by their ability to hasten the kinetic of 
aggregation of PrP. This assay measures the infectivity of any given biological sample, 
in a reasonable time scale, with a high sensitivity to low seed concentration. Moreover, 
further questions can be posed about the possible structures for detecting prions in 
biological samples. Additionally the system has been shown for revealing potential anti-
TSE drugs [221]. 
The protocol can make use of 96-well plates with different platforms (Molecular Devices 
and ThermoLabsystems) and different buffer conditions (Fig. 38). 
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Fig. 38. Parameters of two protocols used to develop PrP aggregation protocol in a 96-well plate format. 
On the left condition published for revealing anti-TSE drugs properties, on the right for detecting prions in 
biological sample. 
 
The main focus of my PhD studies was to analyse in detail the process of fibril formation 
using the ASA assay. Firstly, the initial analysis of the reaction of fibril formation was 
carried out using a discontinuous assay due to the fact that it is historically the protocol 
to study amyloid formation. However, I switched to the continuous assay, which uses a 
96-well plate, in order to develop this particular assay system. 
The parameters of the assay used for making the fibrils, was the same as the one used 
by Colby et al.: Spectramax M5 (Molecular Devices) 600 rpm at 37°C. In order to 
assess the ASA assay, one parameter was changed for the experimental assay: the 
concentration of GdnHCl. Intriguingly, the ASA protocol uses only one glass bead (3 
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mm) inside each well in contrast to that of the protocol by Breydo et al. [234] which uses 
3 beads (Fig. 37B and Fig. 38).  
Two different concentrations GdnHCl were used: 2 M and 0.4 M. These two 
concentration of denaturant were chosen, because the former concentration is routinely 
used for fibril production and gives a good production of fibrils, while the latter is used 
for detecting the infectivity in biological samples [194]. GdnHCl is known to alter protein 
structure. In the presence of 2 M GdnHCl we observed that recPrP folded completely 
into a random coil whereas in the presence of 0.4 M GdnHCl, recPrP is mainly α-helical. 
This latter condition was also postulated and demonstrated with the same concentration 
of urea [166]. Recently, studies have shown an existence of a strong correlation 
between the conformational stability of synthetic prions, (determined from PK digestion 
assays) and the incubation period to prion disease [91]. To explain this relationship 
between the stability of fibrils and their infectivity, they authors of the study proposed 
that the conformational stability of amyloid fibrils determines their intrinsic fragility and/or 
the size of the smallest possible fibrillar fragments. Recently, this model was sustained 
by analysis of aggregates made in different growth conditions [210].  
Interestingly, the kinetic output data was modulated by the concentration of GdnHCl. In 
difference to that was seen using the discontinuous assay, the increase of concentration 
of GdnHCl reduces the lag phase. However the maximum rate was obtained at 2 M 
GdnHCl.  An increase in the concentration of GdnHCl above 2 M gives a small 
decrease in the lag phase in comparison to that one seen in the concentration range 
between 0.4 to 2 M GdnHCl. The strength of the denaturing environment has an 
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important impact in the range of possible amyloid structures with those exhibiting high 
conformational stability.  
An aim of these experiments was to find a common structural characteristic of the 
aggregate formed. Moreover, the main question was to assess if there were different 
structures formed under the different concentrations. To this aim, a combined AFM and 
biochemical characterization analysis was performed. The AFM analysis was performed 
with the help Dr Alpan Bek. We observed, by a systematic analysis of the different 
growth conditions, that the growth conditions impacted greatly, the assembly of 
aggregates.  
We observed a production of long fibrils using 2 M GdnHCl but only small aggregates 
using 0.4 M GdnHCl. These differences were also revealed by a different max intensity 
of ThT. 
The ThT dye shows a strong increase in fluorescence upon binding to amyloid fibrils 
and has hence become the most commonly used amyloid-specific dye. In spite of this 
widespread use, the mechanism underlying specific binding and fluorescence 
enhancement upon interaction with amyloid fibrils remains largely unknown. 
Nevertheless, ThT fluorescence enhancement is strongly dependent on fibril 
morphology. Our data highlights the fact that the profile of data gives a direct indication 
of the aggregation process. Furthermore, a difference in the maximum fluorescence 
intensity from 2 M GdnHCl preparation to 0.4 M GdnHCl was seen. The differences 
enable an analysis of the seeding effect in detail. The catalytic and the templating 
effects, the two key features of the amyloid and prion replication, were intimately 
coupled due to the self-replicating nature of the cross-β structure. The catalytic effect 
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was observed also in the analysis of the kinetic profile. The templating effect was also 
demonstrated using ThT intensity. In fact the intensity obtained with cross seeding is not 
the same as that from the initial analysis. This effect has also been seen in earlier 
experiments using cross seeding from mouse fibrils and hamster fibrils [234, 235]. 
Under the growth condition in 0.4 M GdnHCl, seeding had a different impact to that as 
seen in 2 M GdnHCl. In fact, the homo-seeding condition at 2 M GdnHCl is significantly 
different to the seeding made by 0.4 M GdnHCl. However, the seeding experiment 
suggests that  low concentration of GdHCl can help to reveal seed effect. Recently, 
Baskakov et al. showed that the effect of seeding can be separated between the 
catalytic effect and templating effect. The catalytic effect can be visible also with the 
absence of the templating effect as demonstrated in different recent works [233]. This 
result is in agreement with our results. In fact, a max intensity of ThT as a marker of 
templating effect it was found only the catalytic effect (no seed-specific structure eredity) 
(data not shown). However, we observed the possibility to reveal the infection molecule 
also in the cells culture. In fact, we observed a seeding effect using PTAScGT1 cells but 
not in PTAGT1 cells. This is in agreement to the fact the ASA protocol can be useful to 
that scope. However we observed the catalytic effect also at 2 M GdnHCl. 
Inoculation of β-pleated fibrils formed by one protein was sufficient to cause or 
accelerate the in vivo amyloidosis of an unrelated protein in animals [153]. This result 
suggests the necessity to define in detail the seeding structure definition.  
To elucidate more details of structure recPrP in amyloid fibrils, this structure was 
analysed both at the start and at the end of the preparation under different 
concentrations. The protein, under the conditions of the ASA assay, shows mainly an α-
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helical fold. This suggests therefore that the data obtained in this study highlights the 
importance of the growth condtions of the fibril for the structure of the aggregate formed. 
This difference is important in order to explain the heterogeneity of the aggregate  
preparations. The random coil structure enabled a production of fibrils with a particular 
assembly in a constant reproducible manner.  
Interestingly, the impact of the growth condition revealed from a detailed analysis of the 
aggregates, a particular distribution of the height of the amyloid assemblies: height of 8 
nm and 5.7 nm for the preparation of 2 M GdnHCl. Preparations of 2 M GdnHCl showed 
fibrils with height profile more than 8 nm (12-20 nm). Preparations also revealed a 
monodispersity using DLS instruments suggesting a homogeneity in the preparation 
sizes is aided by the glass beads (Fig. 41). Moreover, this occurrence suggests that the 
assembly of higher-order fibrils occurred predominantly in the vertical dimension via the 
stacking of ribbons on top of one another, with the association in the lateral dimension 
being limited.  
Fibrils prepared with 2 M GdnHCl also displayed twists in the fibrils. SAFs (scrapie 
associated fibrils) extracted from a single source, typically include fibrils consisting of 
filaments aligned in parallel arrays, fibrils formed by helically twisted filaments, fibrils 
with a “spaghetti-like” wavy appearance, and fibrils with undefined morphologies. 
Ultrastructural studies of the full-length PrP, by atomic force microscopy and  TEM 
reveal extremely broad polymorphism in fibrils formed under a single growth condition 
[226]. Detailed analysis of ultrastructure was attributed to a fibrils with a major subtype 
height 3.61±0.28 nm, composed of two ribbons, each of which was composed of two 
filaments. These studies were made, using the same condition used for the production 
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of the first synthetic prion [87]}. Unexpectedly, the 2 M GdnHCl condition gave fibrils 
with a particular distribution of height. In 0.4 M GdnHCl growth condition we found 
aggregates with a similar height profile to that of the aggregates made using a protocol 
to produce synthetic prions: 3.2 nm and 5.7 nm. A detailed analysis of the volume of the 
particles suggests the possibility that each aggregate has a variable number of 
molecules (Fig.39). 
 
 
Fig. 39. Number of molecule of MoPrP(89-230) composing aggregates at 0.4 M GdnHCl. This analysis 
was based on a estimation of the volume of MoPrP(89-230) in 15 nm3.  
 
However, in the fibril preparation in 2 M GdnHCl, the solutions contain a polydispersed 
distribution of the aggregates. Moreover, testing the influence of glass beads showed an 
effect in the kinetics of the aggregates (Fig. 40) also revealed an effect in the size of 
aggregates by DLS (Fig. 39). 
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Fig. 40. A: Kinetic curve of MoPrP(89-230) of 2 M and 0.4M GdnHCl in presence of glass beads. B: 
Kinetics curves of MoPrP(89-230) of 2 M and 0.4M GdnHCl in absence of glass beads. 
 
Therefore this data suggests that the associate structure in the ThT intensity profile is 
not of a particular aggregate form. This could explain why the height of 5.7 nm, as was 
found in both preparation conditions, probably is in a protofibrillar state and common to 
both conditions.  
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The morphological diversity of the fibrils has been previously proposed to appear as a 
result of a variation in nucleation events. The data here, suggests that the denaturation 
state can affect both the nucleation event and the aggregate morphology. Many models 
of structure of prion aggregates have been proposed but the heterogeneity of the 
preparation makes it difficult to sustain a unique model. The data in this study appears 
not to support either the model as proposed by Govearts et al. [196] but is in agreement 
what suggested by Caughey group [236] This is supported by the minimum height of the 
packed fibrils which is in agreement by the spiral model [197]. However the Spiral model 
does not account for the cross-β fiber X-ray diffraction and that is a great limitation in to 
validate that model. This study has certain limitations but is in agreement with that as 
proposed by previous authors [236] showing that the structure proposed by Govaerts et 
al. and by the recent publication by Anderson et al., that aggregates made in vitro are 
not similar to prion fibrils produced in vivo. However the in vitro aggregates have more 
similarity with a particular structure encoded in the SAF fibrils. Recently unpublished 
result show how  X-ray diffraction patter of PrPSc are different with the patter obtain 
starting by recombinant source. In conclusion, more details on the structural 
relationships between prion fibrils and SAF fibrils, in contrast with other strains or 
infective aggregates should be undertaken. Moreover, the data from this study shows 
that the continuous assay in a 96-well plate has the possibility (using different growth 
conditions) to differentiate aggregates in terms of their structural morphology and their 
kinetics traces. One important parameter can be use for that purpose is the 
concentration of GdnHCl but also the pH and the type of agitation.  
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Altogether, these results suggest the need to further investigate several other 
biophtsical conditions. In other words, the approach presented in detail above provides 
new insights into a new methodology of how to prepare a new generation of synthetic 
prions and suggest the necessity to improve our knowledge of prion structure and its 
function.
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APPENDIX I: MATHEMATICAL APPROACH 
Method for fitting kinetic profile of MoPrP(89-230) 
 
The kinetics and products of protein aggregation have been measured using at least 18 
different analytical techniques, each having its own intrinsic advantages and 
disadvantages [237]. Typical kinetics of spontaneous in vitro fibril formation of 
MoPrP(89-230) at 37°C showed a substantial lag-phase followed by a rapid increase of 
amyloid fibrils accumulation as measured by ThT fluorescence. The length of the lag-
phase is a important parameter as it can help to detect any effect on the fibril formation. 
In fact, the difference of the lag phase was used to detect the propensity of prion 
transmission [166, 174, 224]. 
The way we can estimated the lag-phase depends on the type of equation used. 
Therefore, I use three different approaches based on the different starting hypothesis.  
The first method was the qualitatively method: this method is base on the fact the 
operator estimated the lag-phase in function of is experience. This method was used in 
many papers and don’t have any physical meaning. This method was also used by 
Colby et al. [194] as a base for detecting the infectivity in biological samples. In fact, 
after the determination of the lag phase, the error was estimated using ANOVA 
procedure. 
 112 
[162, 166, 212, 224]. The second method is base on the sigmoidal curve develop by 
Cholberg et al. [223]. The authors are careful to note that, “This expression is unrelated 
to the underlying molecular events, but provides a convenient method for comparison of 
the kinetics of fibrillation”[223]. These empirical equation has been used to analyze 
numerous data sets thus allowing for comparisons to be made between related data 
sets [162, 166, 174, 222, 226].  However, meaningful kinetic and mechanistic 
information is lacking. 
The data were fit to a sigmoidal equation (Eq 1) using  
 
F ) (Fi + mit) + (Ff + mft)/{1 + exp[-(t - tm)/τ]} (Eq.1) 
 
where F is the fluorescence intensity and tm is the time to 50% of maximal fluorescence. 
The initial baseline during the lag time is described by Fi + mit. The final baseline after 
the growth phase has ended is described by Ff + mft. The apparent rate constant, kapp, 
for the growth of fibrils is given by 1/τ, the lag time is calculated as tm – 2τ, and the 
amplitude, amp, is given by Ff - Fi. Although Eq 1 gave very good fits for the ThT kinetics 
profiles, the expression is strictly a simple empirical means of providing kinetics 
parameters for comparing rates of fibrillation from different samples and does not 
directly reflect the underlying complex kinetics scheme. 
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Third method was base by quadratic and exponential functions that describe nucleation 
and elongation stages of fibril formation. These functions are limiting forms of hyperbolic 
cosine solution (Equation 2) of the first-order approximation of the reaction equation 
developed by Bishop and Ferrone [209]. for analysis of the nucleation-controlled 
polymerization. 
F = A(cosh Bt – 1), F   ½ B2A t2 at Bt   0, F 
  ½ A eBt at Bt ›› 1, Eq. 2 
where F = observable parameter (ThT Fluorescence), t = polymerization time, A and B 
= fitting coefficients.  
These method was used for estimated the length of lag-phase. Toward this aim we use 
a statistic program for intimately rapidly the lag-phase value. Therefore we use R 
Program (http://www.r-project.org/) a open source program give a opportunity to write a 
simple script to analyzed many data sets. 
Thanks to the precious help of Prof. Corrado Lagazio it was wrote a script for any type 
of equation for estimated the lag phase. Each kinetics profile obtain by different growth 
condition was import by the R program and Normalized. Then the data was fitted using 
all equation describe above. 
Program after many iteration give at the end a simple table with the lag phase 
estimation. For any analysis give the confidence of the reading and a PDF image to 
evaluated the properly fitting kinetics (Fig. 1). 
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Fig. 1. Example of the normal procedure of analysis using R program. 
The estimated lag phase was compare using R program using one way ANOVA. 
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APPENDIX II: Atomic Force Microscopy (AFM) 
 
The atomic force microscope (AFM) is one of the foremost tools for imaging, measuring and 
manipulating matter at the nanoscale.This technique uses a probe that consist of a sharp tip at 
the end of a micromachined cantilever generally made of Silicon or Silicon Nitride. The tip 
interacts with the sample or better with the surface of the sample, at the atomic level through 
attractive or repulsive forces, depending on the imaging regime. AFM tip determines with its 
structure the interactions with the surface. The values of these interactions are recorded while 
the tip and the cantilever are scanned on the sample surface allowing the reconstruction of the 
sample topography with sub nanometric high resolution. The tip moves in one direction and 
returns in the opposite direction generating two images (trace and retrace image) of the same 
scanline. When all the parameter are set correctly trace and retrace images should be identical. 
When instead the tip interact and modify the sample trace and retrace could appear dramatically 
different (see picture below). 
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APPENDIX III: Insulin Amyloid Fibril Formation 
 
Introduction 
Insulin, a small hormone protein consisting of two polypeptide chains, adopts an α-
helical conformation in its native state. The insulin sequence is well conserved among 
mammalian species, with few variations. Two polypeptide chains are linked by two 
interchain and one intrachain disulfide bridges [238]. Although insulin does not appear 
to be directly involved with any known human amyloid diseases, native insulin does 
readily convert to an inactive fibrillar form under a wide range of conditions [239]. In one 
clinical study, amyloid fibril–like deposits containing insulin were found at sites of insulin 
injections in a diabetic patient [240]. An interesting feature of insulin is that its three 
disulfide bridges are retained in the in vitro and ex vivo fibrillar form [238, 241] [242] 
[243]. Thus, these disulfide bonds must constrain the possible conformational 
rearrangements during the α-helix to β-sheet transition [243]. This conformational 
constraint makes insulin a unique model system for studying protein misfolding and 
subsequent amyloid fibrillization. 
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Material and Methods 
Preparation of Insulin Protein 
Bovine insulin and all other chemicals were of analytical grade or better and were 
obtained from Sigma–Aldrich and used without further purification. Solutions were made 
up by weighing out the required amount of insulin and dissolving the dry powder in 
distilled and deionized water adjusted to pH 2 with HCl. The pH was then checked and, 
if necessary, adjusted with solutions of HCl or NaOH. It was found by UV absorption at 
280 nm that insulin concentrations obtained by this method were precise to within 10%. 
Solutions were incubated in glass vials at temperatures of 37°C or 65°C for up to 24 h. 
These protocol was follow in agreement of what publish in 2005 [244] 
The fibril preparation has been diluted in buffer solution to a concentration of 10µM and 
cooled at 0oC. A droplet has been dispersed on a freshly cleaved mica substrate. After 
1 minute the sample has been washed in DI water and blown dry with air (N2 is not yet 
available). 
Thioflavin-T (ThT) Measurements. 
 Aliquots (5 µl) of insulin solutions after incubation were added to 995 µl of a 10 mM 
Na2H/NaH2PO4, 150 mM NaCl, and 50 µM ThT solution and stirred for 30 s. By using a 
fluorescence spectrophotometer (Cary Eclipse, Varian), fluorescence emission intensity 
was measured for 30 s at 482 nm (10-nm slit width), exciting at 440 nm (5-nm slit 
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width). Values were compared with those of the ThT solution and of samples taken from 
the insulin solution before any incubation. 
Atomic Force Microscopy (AFM). 
 AFM images has been acquired in tapping mode and in true non contact mode with 
three different tip, from different tip provider (NT-MDT, Nanoworld, ParkScientific 
instruments). The nominal tip radius was in all the three cases about 10nm, the 
oscillation frequency was 160kHz, 260kHz and 83kHz respectively. Scanning velocity 
was kept between 0.5 to 16mm/sec.n. 
Results and Discussion 
Insulin was incubated at 65°C for 24 h. The reaction was followed using a ThT intensity. 
The lag phase obtained was 22.3±1.12 hours  and the kinetics follow a sigmoidal curve. 
It was follow using a typical approach of discontinuous assay. The protocol use is base 
on a a paper that describe the reaction was terminate up to 24 hours at 65°C. 
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Fig. 1. Kinetics profile of insulin fibrils with ThT. The reaction was performed at 65 °C for 24 
hours. 
 
 
At the end of the reaction, sample was analyzed using atomic force microscopy (AFM). 
In Fig. 2 it was put enlighten the process of aggregation have success. In the sample 
some long fibrils (>2µm) were found. 
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Fig. 2. AFM analysis of the product of aggregation of insulin protein. Fibrils shows a typical image 
over an area of 2x2µm. In larger images, using standard digitalization parameters (256x256 or 512x512) 
the pixel size is comparable or larger than the lateral size of the fibrils, and some details are lost. Fibrils 
appear randomly distributed with several crossings and some loop. Fibril length often exceeds 2µm (the 
scanning area).  
 
Statistic analysis of the insulin fibrils show that typically the fibrils height is 2.5 – 3 nm. 
Some bundles of fibrils are also present with height never exceeding 10nm.  The height 
distribution was show some particular peaks 10.8 nm, 3.8 nm. Analysis of different 
region taken with a larger magnification, where all the fibrils are 3nm height. The width 
of the fibril as measured by AFM range from 10 to 20 nm (Fig. 4). Even if nominally the 
three tips used are identical, fibrils appeared narrower with the 2nd tip. In order to 
obtained a more precise evaluation of the lateral size. 
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Fig. 3. Height distribution of the image shown in Fig. 1. Typically the fibrils heigh is 2.5 – 3 nm. Some 
bundles of fibrils are also present with height never exceeding 10 nm. 
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Fig. 4. A different region taken with a larger magnification, where all the fibrils are 3 nm in height. The 
width of the fibril as measured by AFM range from 10 to 20 nm, depending on the tip used. Typically the 
observed width is the result of the convolution of the sample size and the tip size. 
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Fig. 5. Details of Fig. 3A.  An height profile has been obtained along the fibril marked with a straight line 
B Structures with a periodicity of about 70 nm are highlighted.  
 
Insulin fibrils report a particular periodicity  of the height along straight line about 70 nm 
like it was show in fig 5B. This fits rather well with the twisted structure already reported 
in literature and observed by TEM spectroscopy [223]. 
Insulin fibrils show some twisted fibrils; these data is in agremment what was reported 
by other authors. 
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Fig. 6. A large area picture in which the colour scale has been set in order to highlight the twisted 
structures on the 3 nm height fibrils. 
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Fig. 7. Lock in phase of insulin aggregates. On the left panel a standard height image is displayed 
while on the right panel an image where the phase delay between excitation and tip oscillation is plotted. 
 
 
The lock phase of the fibrils reported in Fig. 8 show the  different resistance of insulin 
and mica surface. In fact the phase delay is significantly different when the tip interacts 
with the mica and when the tip interacts with the fibrils. This can be attributed to a 
different hydrophilicity of the two materials, or to different mechanical and/or dissipative 
properties. Maybe we should try to use this effect to distinguish different kind of fibrils. 
The differences at the borders (yellow) are due instead to the feedback delay. 
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Fig. 8. Lock phase of Insulin fibrils.  
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APPENDIX IV: α-Synuclein Amyloid Fibril Formation 
Materials and Methods 
Expression of α-synuclein 
E. coli strain BL21 cells were transformed with the WT and mutant α-synuclein 
constructs (pET11a:Syn, kindly gave by Professor Gustinchic and dr. Alessandra 
Chesi). One bacterial colony was inoculated into 5 mL LB broth containing 100 µg/mL 
ampicillin (QBiogene,Serva), and incubated overnight at 37°C with continuous shaking. 
Overexpression of the protein was achieved by transferring 2.5 mL pre-culture to 500 
mL LB medium supplemented with 70 µg/mL ampicillin. Cells were grown at 37°C, with 
continuous shaking to an OD600 nm of about 0.4-0.6 followed by induction with 1 mM 
isopropyl-β-thiogalactopyranoside (IPTG) for 3 h. After induction, the bacterial cells 
were harvested by centrifugation at 5000 g for 10 min and stored at -80°C. 
It was also made α-synuclein using bioreactor (BiostaB-plus 2L Sartorius). Single cell 
was inoculated in  200 mL of  LB o/n at 37°C. Following morning  it was inoculate in 2 L 
fermentator with 1.8 L of LB media  with 50 mL of preculture. After  reach 0.8 OD  
bacterial was induce with 1mM IPTG for 8 hours. 
The cell pellet was re-dissolved in 50 mM Tris (Applichem), 50 mM KCl (Applichem), 5 
mM MgAc (Applichem), 0.1% Sodium Azide (Applichem), pH 8.5 (250 mg pellet/mL of 
buffer). The cell suspension was sonicated for 10 minutes, and the lysate was 
centrifuged at 8000 g for 30 min. The supernatant was separated from the pellet and the 
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former was first boiled for 20 min, then centrifuged at 8000 g for 30 min, and finally 
filtered through a 0.22 µm filter (Millipore).  
Purification α-synuclein 
The protein was firstly purified through anion exchange chromatography (HiPrep Q FF 
column, Amersham) in 20 mM Tris, pH 8, 20 mM Tris, 1 M NaCl, pH 8 followed by 
injection onto a size exclusion chromatography column (Superdex 200 26/30 
Amersham) in 50 mM Tris/HCl, pH 7.5. Purified preparations were dialyzed against 
water for approximately 24 h, then lyophilized and stored at -80°C until use. 
Fibrillization conditions 
To characterize the aggregation properties of WT and mutant α-synuclein proteins were 
dissolved in 20 mM Tris (Aldrich)/150 mM sodium chloride (Aldrich), pH 7.4, at a 
concentrationof 100 fM (500 µL total volume in a 1.5 mL test-tube). The concentration of 
α-synuclein was determined using its _molar extinction coefficient at 280 nm (i.e. 
ε280=5120) ona Cary 100 Bio spectrophotometer. The purified proteins were then 
subjected to fibrillization  conditions in absence or presence of an equimolar quantity of 
dopamine hydrochloride (Fluka) at 37 °C with continuous shaking for the indicated time 
points. 
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ThT assay. 
 
Fibril formation was monitored by the ThT assay, which was performed by combining10 
µL of aggregated α-synuclein with 80 µL of 50 mM Glycine-NaOH (Fluka), pH 8.5, and 
10 µL of 100 µM ThT (Sigma) in water. Fluorescence measurements were recorded in 
an LSB 50 (Perkin Elmer). 
 
Results and Discussion 
α-synuclein was expressed using pET11a-syn in flask and also in bioreactors Biostat B 
plus (Sartorius). 
α-synuclein gave a high expression in both approach and the protein was successfully 
purify using a protocol from Lansbury Lab.  Kinetics experiments demonstrate is it 
possible to obtain fibrils using 96 plate with one glass beads inside. The kinetics 
obtained demonstrate a low reproducibility. However it after 100 hour of agitation at 
37°C the analysis of the sample show presence of the fibrils. Detailed analysis of the 
height distribution put enlighten two height peaks  10.8 µm and 3.8 µm. 
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Fig .1. Expression of Synuclein obtained in bioreactor (Biosta B plus) M, Marker ,1: one oD of Inoculum in 
the bioreactor; 2 one OD of before induction;3 After 4 hours of induction with 1mM IPTG; 4: after o/n 
induction. 
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Fig. 2. A: Kinetics profile of α-synuclein in plate readers. B: Example of topography of fibrils obtained 
from α-synuclein protein. 
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